• Become A Proficient Trader With Our Comprehensive Trading Course
    Held by our renowned Trader, Mr.Altsignals!
    Aspiring to be a successful trader? Whether you're starting from scratch or looking to enhance your trading skills, our comprehensive trading course is your gateway to success. Designed for everyone - from beginners to those looking to refine their strategies.
    Follow our on Web: https://bit.ly/MarketAnalysisASI
    What We Offer:
    Unified Comprehensive Course ($799): Our all-in-one course covers a wide range of essential topics for traders. You'll learn about:
    - Introduction to financial markets
    - Basics of technical analysis
    - Various types of charts
    - Candlestick patterns
    - Trend recognition
    - Understanding gaps
    - Different timeframes
    - Moving averages
    - Fibonacci tools
    - Volume analysis
    - Pivot points
    - Trendlines and channels
    - Indicators and oscillators
    - Divergence concepts
    - Tips on Ichimoku and fractals
    - Price and chart patterns
    - Mindset, strategy creation, and risk management
    All this is divided into classes.
    12 - 15 sessions, 2-3 sessions per week, each session 1HR - 1.5 HR
    Exclusive VIP Telegram Channel Access: Connect with our private community for continuous learning and support.
    Full Support from Altsignals: Get expert insights and guidance from our renowned analyst Mr. B (Check examples of his performance:
    - Marketing: [email protected]
    - Press: [email protected]
    - Admin: [email protected]
    - Buy Assistance: [email protected]
    Comprehensive Curriculum: This course is designed to make you a well-rounded trader, covering everything from the basics to advanced trading techniques.
    * Why Choose Our Course?

    Tailored for All Levels: Perfect for both novices and experienced traders.
    Expert Guidance: Learn from and interact with our expert analyst, Mr. B.
    Incredible Value: Comprehensive trading education at an unbeatable price.
    * Only 10 seats available - Embark on Your Trading Journey!
    Secure your spot in our first session. Elevate your trading skills and join a community of passionate traders.
    Sign Up Today! Get in touch with @altsignalssupport

    / Unbelievable Gains with AltSignals Binance Futures VIP! /
    Our traders are on fire!
    With 5 open signals, we're achieving remarkable results that are turning heads in the crypto world:
    GMT: +31% profit at 3x leverage
    FLOW: +39% profit at 3x leverage
    AVAX: An astounding +198% profit at 5x leverage
    ATOM: +107% profit at 5x leverage
    SAND: A solid +100% profit at 4x leverage
    What makes these gains even more astonishing? We're achieving them with relatively low leverage. Our strategy is all about minimizing risk while maximizing profit potential.
    Don't miss out on this opportunity to join AltSignals Binance Futures VIP (https://bit.ly/MarketAnalysisASI) and take advantage of our proven trading signals. Elevate your trading game today!
    Become A Proficient Trader With Our Comprehensive Trading Course Held by our renowned Trader, Mr.Altsignals! Aspiring to be a successful trader? Whether you're starting from scratch or looking to enhance your trading skills, our comprehensive trading course is your gateway to success. Designed for everyone - from beginners to those looking to refine their strategies. Follow our on Web: https://bit.ly/MarketAnalysisASI 🏆 What We Offer: ✅ Unified Comprehensive Course ($799): Our all-in-one course covers a wide range of essential topics for traders. You'll learn about: - Introduction to financial markets - Basics of technical analysis - Various types of charts - Candlestick patterns - Trend recognition - Understanding gaps - Different timeframes - Moving averages - Fibonacci tools - Volume analysis - Pivot points - Trendlines and channels - Indicators and oscillators - Divergence concepts - Tips on Ichimoku and fractals - Price and chart patterns - Mindset, strategy creation, and risk management All this is divided into classes. 12 - 15 sessions, 2-3 sessions per week, each session 1HR - 1.5 HR ✅ Exclusive VIP Telegram Channel Access: Connect with our private community for continuous learning and support. ✅ Full Support from Altsignals: Get expert insights and guidance from our renowned analyst Mr. B (Check examples of his performance: - Marketing: [email protected] - Press: [email protected] - Admin: [email protected] - Buy Assistance: [email protected] ✅ Comprehensive Curriculum: This course is designed to make you a well-rounded trader, covering everything from the basics to advanced trading techniques. * Why Choose Our Course? ✅Tailored for All Levels: Perfect for both novices and experienced traders. ✅Expert Guidance: Learn from and interact with our expert analyst, Mr. B. ✅Incredible Value: Comprehensive trading education at an unbeatable price. * Only 10 seats available - Embark on Your Trading Journey! Secure your spot in our first session. Elevate your trading skills and join a community of passionate traders. Sign Up Today! Get in touch with @altsignalssupport / Unbelievable Gains with AltSignals Binance Futures VIP! / Our traders are on fire! 🔥 With 5 open signals, we're achieving remarkable results that are turning heads in the crypto world: ✨ GMT: +31% profit at 3x leverage ✨ FLOW: +39% profit at 3x leverage ✨ AVAX: An astounding +198% profit at 5x leverage ✨ ATOM: +107% profit at 5x leverage ✨ SAND: A solid +100% profit at 4x leverage What makes these gains even more astonishing? We're achieving them with relatively low leverage. Our strategy is all about minimizing risk while maximizing profit potential. Don't miss out on this opportunity to join AltSignals Binance Futures VIP (https://bit.ly/MarketAnalysisASI) and take advantage of our proven trading signals. Elevate your trading game today!
    BIT.LY
    AltSignals - #1 Best Crypto Signals
    Join AltSignals VIP - The Best Telegram Crypto Signals. Daily Trading Signals for Binance Futures, Spot & Forex since 2017. Over 50K Members!
    Yay
    1
    0 Comments 0 Shares 1059 Views
  • Young Dolly Parton lived in a cabin with her family of 14 & bathed in the nearby river. Today, she spends her millions on those in need.
    Dolly Parton was born in a one-bedroom cabin in rural Tennessee. Her dad was a sharecropper who couldn't read. As the family grew, the older children got more responsibilities, and Parton, the fourth of 12 children, had to look after her younger siblings.
    The kids didn't even have their own beds, and they slept three to four in a bed. They spent most of the time outside because the cabin was too small for them to hang out comfortably. The space outside served as an extension for sharing meals, entertainment, and playing games.
    Parton has always been open about discussing her humble beginnings or how this influenced her views on life. She came from a large family with limited resources, so she is familiar with the challenges of being poor.
    In fact, fans love Parton for her singing and unique glam-country queen image. They also love her for her generous soul. She spends much of her income on philanthropy efforts, focusing on education, health, and disaster relief.
    Parton's outward appearance may be attractive, but her inner beauty is definitely captivating.
    Credit: Hollywood Elite
    Young Dolly Parton lived in a cabin with her family of 14 & bathed in the nearby river. Today, she spends her millions on those in need. 🙏 Dolly Parton was born in a one-bedroom cabin in rural Tennessee. Her dad was a sharecropper who couldn't read. As the family grew, the older children got more responsibilities, and Parton, the fourth of 12 children, had to look after her younger siblings. The kids didn't even have their own beds, and they slept three to four in a bed. They spent most of the time outside because the cabin was too small for them to hang out comfortably. The space outside served as an extension for sharing meals, entertainment, and playing games. Parton has always been open about discussing her humble beginnings or how this influenced her views on life. She came from a large family with limited resources, so she is familiar with the challenges of being poor. In fact, fans love Parton for her singing and unique glam-country queen image. They also love her for her generous soul. She spends much of her income on philanthropy efforts, focusing on education, health, and disaster relief. Parton's outward appearance may be attractive, but her inner beauty is definitely captivating. ✨💖 Credit: Hollywood Elite
    0 Comments 0 Shares 1670 Views
  • Techugo Academe: Igniting Learning Journeys with Tailored Education Apps

    Techugo Academe pioneers in crafting bespoke education apps, revolutionizing learning experiences globally. Our proficient team blends innovation and expertise to develop personalized apps that cater to diverse educational needs. From interactive learning tools to seamless content delivery, we ensure engaging platforms for students, educators, and institutions alike. As a leading education app development company, Techugo Academe is committed to igniting transformative learning journeys and shaping the future of education.

    for more info visit:
    https://www.techugo.com/education-app-development

    #educationappdevelopmentcompany
    #mobileappdevelopmentcompany
    #appdevelopmentcompany
    Techugo Academe: Igniting Learning Journeys with Tailored Education Apps Techugo Academe pioneers in crafting bespoke education apps, revolutionizing learning experiences globally. Our proficient team blends innovation and expertise to develop personalized apps that cater to diverse educational needs. From interactive learning tools to seamless content delivery, we ensure engaging platforms for students, educators, and institutions alike. As a leading education app development company, Techugo Academe is committed to igniting transformative learning journeys and shaping the future of education. for more info visit: https://www.techugo.com/education-app-development #educationappdevelopmentcompany #mobileappdevelopmentcompany #appdevelopmentcompany
    0 Comments 0 Shares 1061 Views
  • Become A Proficient Trader With Our Comprehensive Trading Course

    Held by our renowned Trader, Mr.Altsignals!
    Aspiring to be a successful trader? Whether you're starting from scratch or looking to enhance your trading skills, our comprehensive trading course is your gateway to success. Designed for everyone - from beginners to those looking to refine their strategies.
    Follow our on Web: https://bit.ly/MarketAnalysisASI
    What We Offer:
    Unified Comprehensive Course ($799): Our all-in-one course covers a wide range of essential topics for traders. You'll learn about:
    - Introduction to financial markets
    - Basics of technical analysis
    - Various types of charts
    - Candlestick patterns
    - Trend recognition
    - Understanding gaps
    - Different timeframes
    - Moving averages
    - Fibonacci tools
    - Volume analysis
    - Pivot points
    - Trendlines and channels
    - Indicators and oscillators
    - Divergence concepts
    - Tips on Ichimoku and fractals
    - Price and chart patterns
    - Mindset, strategy creation, and risk management
    All this is divided into classes.
    12 - 15 sessions, 2-3 sessions per week, each session 1HR - 1.5 HR
    Exclusive VIP Telegram Channel Access: Connect with our private community for continuous learning and support.
    Full Support from Mr. B: Get expert insights and guidance from our renowned analyst Mr. B (Check examples of his performance: 1 (https://t.me/altsignals/11616), 2 (https://t.me/altsignals/11687), 3 (https://t.me/altsignals/11778), 4 (https://t.me/c/1440870181/18643)).
    Comprehensive Curriculum: This course is designed to make you a well-rounded trader, covering everything from the basics to advanced trading techniques.
    * Why Choose Our Course?

    Tailored for All Levels: Perfect for both novices and experienced traders.
    Expert Guidance: Learn from and interact with our expert analyst, Mr. B.
    Incredible Value: Comprehensive trading education at an unbeatable price.
    * Only 10 seats available - Embark on Your Trading Journey!
    Secure your spot in our first session. Elevate your trading skills and join a community of passionate traders.
    Sign Up Today! Get in touch with @altsignalssupport

    / Unbelievable Gains with AltSignals Binance Futures VIP! /
    Our traders are on fire!
    With 5 open signals, we're achieving remarkable results that are turning heads in the crypto world:
    GMT: +31% profit at 3x leverage
    FLOW: +39% profit at 3x leverage
    AVAX: An astounding +198% profit at 5x leverage
    ATOM: +107% profit at 5x leverage
    SAND: A solid +100% profit at 4x leverage
    What makes these gains even more astonishing? We're achieving them with relatively low leverage. Our strategy is all about minimizing risk while maximizing profit potential.
    Don't miss out on this opportunity to join AltSignals Binance Futures VIP (https://bit.ly/MarketAnalysisASI) and take advantage of our proven trading signals. Elevate your trading game today!
    Become A Proficient Trader With Our Comprehensive Trading Course Held by our renowned Trader, Mr.Altsignals! Aspiring to be a successful trader? Whether you're starting from scratch or looking to enhance your trading skills, our comprehensive trading course is your gateway to success. Designed for everyone - from beginners to those looking to refine their strategies. Follow our on Web: https://bit.ly/MarketAnalysisASI 🏆 What We Offer: ✅ Unified Comprehensive Course ($799): Our all-in-one course covers a wide range of essential topics for traders. You'll learn about: - Introduction to financial markets - Basics of technical analysis - Various types of charts - Candlestick patterns - Trend recognition - Understanding gaps - Different timeframes - Moving averages - Fibonacci tools - Volume analysis - Pivot points - Trendlines and channels - Indicators and oscillators - Divergence concepts - Tips on Ichimoku and fractals - Price and chart patterns - Mindset, strategy creation, and risk management All this is divided into classes. 12 - 15 sessions, 2-3 sessions per week, each session 1HR - 1.5 HR ✅ Exclusive VIP Telegram Channel Access: Connect with our private community for continuous learning and support. ✅ Full Support from Mr. B: Get expert insights and guidance from our renowned analyst Mr. B (Check examples of his performance: 1 (https://t.me/altsignals/11616), 2 (https://t.me/altsignals/11687), 3 (https://t.me/altsignals/11778), 4 (https://t.me/c/1440870181/18643)). ✅ Comprehensive Curriculum: This course is designed to make you a well-rounded trader, covering everything from the basics to advanced trading techniques. * Why Choose Our Course? ✅Tailored for All Levels: Perfect for both novices and experienced traders. ✅Expert Guidance: Learn from and interact with our expert analyst, Mr. B. ✅Incredible Value: Comprehensive trading education at an unbeatable price. * Only 10 seats available - Embark on Your Trading Journey! Secure your spot in our first session. Elevate your trading skills and join a community of passionate traders. Sign Up Today! Get in touch with @altsignalssupport / Unbelievable Gains with AltSignals Binance Futures VIP! / Our traders are on fire! 🔥 With 5 open signals, we're achieving remarkable results that are turning heads in the crypto world: ✨ GMT: +31% profit at 3x leverage ✨ FLOW: +39% profit at 3x leverage ✨ AVAX: An astounding +198% profit at 5x leverage ✨ ATOM: +107% profit at 5x leverage ✨ SAND: A solid +100% profit at 4x leverage What makes these gains even more astonishing? We're achieving them with relatively low leverage. Our strategy is all about minimizing risk while maximizing profit potential. Don't miss out on this opportunity to join AltSignals Binance Futures VIP (https://bit.ly/MarketAnalysisASI) and take advantage of our proven trading signals. Elevate your trading game today!
    BIT.LY
    AltSignals - #1 Best Crypto Signals
    Join AltSignals VIP - The Best Telegram Crypto Signals. Daily Trading Signals for Binance Futures, Spot & Forex since 2017. Over 50K Members!
    Like
    1
    0 Comments 0 Shares 2777 Views
  • Cohort Based Learning : Transforming Education Via eLearning Apps

    Cohort Based Learning: Revolutionizing Education Through Interactive eLearning Platforms. Dive into a dynamic educational experience where collaboration meets innovation. Engage with peers in a vibrant digital community, driven by personalized learning journeys. Unleash your potential through curated content, expert guidance, and real-time feedback. Embrace a transformative approach to education, where traditional boundaries dissolve, and knowledge becomes a shared adventure. Join the movement shaping the future of learning, one cohort at a time.

    to know more:-
    https://technotrolls.com/cohort-based-learning-transforming-education-via-elearning-apps/


    #elearningappdevelopmentcompany
    #mobileappdevelopmentcompany
    #mobileappdevelopmentcompanyinriyadh
    #mobileappdevelopmentcompanyinsaudiarabia
    Cohort Based Learning : Transforming Education Via eLearning Apps Cohort Based Learning: Revolutionizing Education Through Interactive eLearning Platforms. Dive into a dynamic educational experience where collaboration meets innovation. Engage with peers in a vibrant digital community, driven by personalized learning journeys. Unleash your potential through curated content, expert guidance, and real-time feedback. Embrace a transformative approach to education, where traditional boundaries dissolve, and knowledge becomes a shared adventure. Join the movement shaping the future of learning, one cohort at a time. to know more:- https://technotrolls.com/cohort-based-learning-transforming-education-via-elearning-apps/ #elearningappdevelopmentcompany #mobileappdevelopmentcompany #mobileappdevelopmentcompanyinriyadh #mobileappdevelopmentcompanyinsaudiarabia
    0 Comments 0 Shares 2462 Views
  • "The End of Gout" is a comprehensive guide and program designed to help individuals manage and potentially eliminate gout, a type of arthritis characterized by sudden, severe attacks of pain, redness, and tenderness in joints. The program is primarily centered around dietary and lifestyle changes, emphasizing natural methods to reduce uric acid levels, which are the main cause of gout attacks.

    Here are the key aspects of "The End of Gout":

    1. Understanding Gout:
    Causes: Gout is caused by elevated levels of uric acid in the blood, which can form crystals in joints and tissues, leading to inflammation and pain.
    Risk Factors: Genetics, diet, obesity, certain medications, and other health conditions like hypertension and diabetes can increase the risk of gout.

    2. Dietary Recommendations:
    Foods to Avoid: High-purine foods such as red meat, shellfish, sugary beverages, and alcohol, particularly beer, which can increase uric acid levels.
    Foods to Include: Low-purine foods like fruits, vegetables, whole grains, and dairy products. Cherries, in particular, are recommended due to their potential to reduce uric acid levels.
    Hydration: Drinking plenty of water to help flush uric acid out of the body.

    3. Lifestyle Changes:
    Weight Management: Maintaining a healthy weight can reduce the risk of gout attacks.
    Exercise: Regular physical activity can help manage weight and reduce uric acid levels.
    Stress Reduction: Managing stress through techniques like meditation and yoga can improve overall health and potentially reduce the frequency of gout attacks.

    4. Supplements and Natural Remedies:
    Vitamin C: Known to help reduce uric acid levels.
    Fish Oil: Anti-inflammatory properties can help reduce gout symptoms.
    Herbal Remedies: Some herbs, such as turmeric and ginger, have anti-inflammatory effects.

    5. Monitoring and Managing Gout:
    Regular Check-ups: Regular monitoring of uric acid levels and overall health with a healthcare provider.
    Medication Management: Understanding when medication might be necessary and how to use it effectively alongside natural remedies.

    6. Scientific Basis:
    The program often cites scientific studies and clinical evidence to support the recommended dietary and lifestyle changes. This includes research on the impact of specific foods and nutrients on uric acid levels and inflammation.

    "The End of Gout" program is essentially about empowering individuals with knowledge and practical strategies to manage gout through holistic and natural means. By focusing on diet, lifestyle, and natural supplements, it aims to provide a sustainable solution to reduce and potentially eliminate gout symptoms.

    "The End of Gout" program offers several benefits for individuals looking to manage and potentially eliminate their gout symptoms. Here are some key benefits:

    1. Reduction in Gout Symptoms:
    Pain Relief: By following the dietary and lifestyle recommendations, individuals often experience a significant reduction in the frequency and severity of gout attacks.
    Reduced Inflammation: The program emphasizes anti-inflammatory foods and supplements, which can help decrease joint inflammation and discomfort.

    2. Lower Uric Acid Levels:
    Dietary Changes: Adopting a low-purine diet can help reduce uric acid levels in the blood, preventing the formation of uric acid crystals in the joints.
    Hydration: Increased water intake helps flush out excess uric acid from the body.

    3. Improved Overall Health:
    Weight Management: The program encourages healthy eating and regular exercise, which can lead to weight loss and improved metabolic health.
    Balanced Nutrition: Emphasizing a diet rich in fruits, vegetables, whole grains, and lean proteins contributes to better overall nutrition and health.

    4. Natural and Sustainable Approach:
    Natural Remedies: The use of vitamins, supplements, and herbal remedies provides a natural alternative to pharmaceutical treatments, with fewer potential side effects.
    Lifestyle Integration: The program's recommendations are designed to be integrated into daily life, making it easier to maintain long-term.

    5. Empowerment and Knowledge:
    Educational Content: The program provides detailed information about gout, its causes, and how different foods and lifestyle choices affect uric acid levels and inflammation.
    Personalized Strategies: Individuals can tailor the program's recommendations to their specific needs and health conditions, leading to more effective management of gout.

    Take Control of Your Gout Today with "The End of Gout" Program!: https://tinyurl.com/3nv4zvpf

    #endofgout, #healthcare, #uricacid, #managinggout, #remedies
    "The End of Gout" is a comprehensive guide and program designed to help individuals manage and potentially eliminate gout, a type of arthritis characterized by sudden, severe attacks of pain, redness, and tenderness in joints. The program is primarily centered around dietary and lifestyle changes, emphasizing natural methods to reduce uric acid levels, which are the main cause of gout attacks. Here are the key aspects of "The End of Gout": 1. Understanding Gout: Causes: Gout is caused by elevated levels of uric acid in the blood, which can form crystals in joints and tissues, leading to inflammation and pain. Risk Factors: Genetics, diet, obesity, certain medications, and other health conditions like hypertension and diabetes can increase the risk of gout. 2. Dietary Recommendations: Foods to Avoid: High-purine foods such as red meat, shellfish, sugary beverages, and alcohol, particularly beer, which can increase uric acid levels. Foods to Include: Low-purine foods like fruits, vegetables, whole grains, and dairy products. Cherries, in particular, are recommended due to their potential to reduce uric acid levels. Hydration: Drinking plenty of water to help flush uric acid out of the body. 3. Lifestyle Changes: Weight Management: Maintaining a healthy weight can reduce the risk of gout attacks. Exercise: Regular physical activity can help manage weight and reduce uric acid levels. Stress Reduction: Managing stress through techniques like meditation and yoga can improve overall health and potentially reduce the frequency of gout attacks. 4. Supplements and Natural Remedies: Vitamin C: Known to help reduce uric acid levels. Fish Oil: Anti-inflammatory properties can help reduce gout symptoms. Herbal Remedies: Some herbs, such as turmeric and ginger, have anti-inflammatory effects. 5. Monitoring and Managing Gout: Regular Check-ups: Regular monitoring of uric acid levels and overall health with a healthcare provider. Medication Management: Understanding when medication might be necessary and how to use it effectively alongside natural remedies. 6. Scientific Basis: The program often cites scientific studies and clinical evidence to support the recommended dietary and lifestyle changes. This includes research on the impact of specific foods and nutrients on uric acid levels and inflammation. "The End of Gout" program is essentially about empowering individuals with knowledge and practical strategies to manage gout through holistic and natural means. By focusing on diet, lifestyle, and natural supplements, it aims to provide a sustainable solution to reduce and potentially eliminate gout symptoms. "The End of Gout" program offers several benefits for individuals looking to manage and potentially eliminate their gout symptoms. Here are some key benefits: 1. Reduction in Gout Symptoms: Pain Relief: By following the dietary and lifestyle recommendations, individuals often experience a significant reduction in the frequency and severity of gout attacks. Reduced Inflammation: The program emphasizes anti-inflammatory foods and supplements, which can help decrease joint inflammation and discomfort. 2. Lower Uric Acid Levels: Dietary Changes: Adopting a low-purine diet can help reduce uric acid levels in the blood, preventing the formation of uric acid crystals in the joints. Hydration: Increased water intake helps flush out excess uric acid from the body. 3. Improved Overall Health: Weight Management: The program encourages healthy eating and regular exercise, which can lead to weight loss and improved metabolic health. Balanced Nutrition: Emphasizing a diet rich in fruits, vegetables, whole grains, and lean proteins contributes to better overall nutrition and health. 4. Natural and Sustainable Approach: Natural Remedies: The use of vitamins, supplements, and herbal remedies provides a natural alternative to pharmaceutical treatments, with fewer potential side effects. Lifestyle Integration: The program's recommendations are designed to be integrated into daily life, making it easier to maintain long-term. 5. Empowerment and Knowledge: Educational Content: The program provides detailed information about gout, its causes, and how different foods and lifestyle choices affect uric acid levels and inflammation. Personalized Strategies: Individuals can tailor the program's recommendations to their specific needs and health conditions, leading to more effective management of gout. Take Control of Your Gout Today with "The End of Gout" Program!: https://tinyurl.com/3nv4zvpf #endofgout, #healthcare, #uricacid, #managinggout, #remedies
    0 Comments 0 Shares 5135 Views
  • Techugo: Expert Tutor Booking App Development for Modern Learning

    As a premier Tutor Booking App Development Company, Techugo excels in creating innovative and user-friendly apps that revolutionize modern learning. Our expert team designs tailored solutions to streamline tutor-student interactions, ensuring seamless booking, scheduling, and communication. Trust Techugo to deliver cutting-edge technology and exceptional user experiences, transforming the way education is accessed and managed. Choose Techugo for top-notch tutor booking app development.

    for more info visit:
    https://www.techugo.com/tutor-booking-app-development

    #tutorbookingappdevelopmentcompany
    #appdevelopmentcompany
    Techugo: Expert Tutor Booking App Development for Modern Learning As a premier Tutor Booking App Development Company, Techugo excels in creating innovative and user-friendly apps that revolutionize modern learning. Our expert team designs tailored solutions to streamline tutor-student interactions, ensuring seamless booking, scheduling, and communication. Trust Techugo to deliver cutting-edge technology and exceptional user experiences, transforming the way education is accessed and managed. Choose Techugo for top-notch tutor booking app development. for more info visit: https://www.techugo.com/tutor-booking-app-development #tutorbookingappdevelopmentcompany #appdevelopmentcompany
    WWW.TECHUGO.COM
    Leading Tutor Booking App Development Company - Techugo
    Revolutionize education with our tutor booking app development. Seamless, secure, and scalable solutions for a future-ready learning experience.
    0 Comments 0 Shares 2176 Views
  • A Deep Dive into School Management Software Development for Modern Education

    Discover the future of education with our comprehensive exploration of school management software development. This deep dive highlights the innovative solutions transforming modern education, making administration seamless and efficient. From attendance tracking to grading systems, learn how these powerful tools enhance communication, streamline processes, and support educators and students alike. Embrace the
    digital evolution in education with cutting-edge software designed to meet the needs of today’s schools. Explore the possibilities and benefits of school management software in this insightful guide.

    for more info visit:-
    https://www.techugo.com/school-software-development

    #schoolmanagementsoftwaredevelopment #topappdevelopmentcompany #mobileappdevelopmentcompany
    A Deep Dive into School Management Software Development for Modern Education Discover the future of education with our comprehensive exploration of school management software development. This deep dive highlights the innovative solutions transforming modern education, making administration seamless and efficient. From attendance tracking to grading systems, learn how these powerful tools enhance communication, streamline processes, and support educators and students alike. Embrace the digital evolution in education with cutting-edge software designed to meet the needs of today’s schools. Explore the possibilities and benefits of school management software in this insightful guide. for more info visit:- https://www.techugo.com/school-software-development #schoolmanagementsoftwaredevelopment #topappdevelopmentcompany #mobileappdevelopmentcompany
    WWW.TECHUGO.COM
    School Management Software Development Company - Techugo
    Enhance your school's efficiency with Techugo's cutting-edge school management software development solutions. Explore now!
    0 Comments 0 Shares 2618 Views
  • https://writinganessay.org/2024/05/27/what-is-the-business-of-education/
    https://writinganessay.org/2024/05/27/what-is-the-business-of-education/
    WRITINGANESSAY.ORG
    What is the business of education - Writing an essay
    Understanding the Business of Education In today’s fast-paced and competitive world, education has become not just a means to gain knowledge but also a lucrative business. From private schools and universities to coaching centers and online tutoring platforms, the education sector has seen a boom in recent years. But what exactly is the business of… Continue reading Untitled
    0 Comments 0 Shares 386 Views
  • Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. While there's no cure for CKD, management and treatment strategies aim to slow its progression, manage symptoms, and reduce complications. Here are some comprehensive strategies and approaches for managing CKD:

    Medical Management
    Blood Pressure Control:

    Use of antihypertensive medications such as ACE inhibitors or ARBs, which can also protect kidney function.
    Regular monitoring and maintaining blood pressure within target ranges.
    Blood Sugar Control (for Diabetic Patients):

    Tight control of blood glucose levels to prevent further kidney damage.
    Use of medications like SGLT2 inhibitors and GLP-1 receptor agonists that have renal benefits.
    Cholesterol Management:

    Use of statins or other lipid-lowering agents to reduce cardiovascular risk.
    Anemia Management:

    Use of erythropoiesis-stimulating agents (ESAs) and iron supplements to manage anemia commonly associated with CKD.
    Phosphate and Calcium Balance:

    Use of phosphate binders and vitamin D supplements to maintain bone health and prevent mineral and bone disorder in CKD.
    Lifestyle Modifications
    Dietary Adjustments:

    Low-sodium diet to help control blood pressure.
    Low-protein diet to reduce the kidneys' workload.
    Avoiding high-phosphorus foods to prevent mineral imbalance.
    Maintaining a healthy weight through balanced nutrition.
    Fluid Management:

    Proper hydration while avoiding overconsumption of fluids to prevent swelling and high blood pressure.
    Smoking Cessation:

    Quitting smoking to improve overall cardiovascular health and reduce further kidney damage.
    Regular Exercise:

    Engaging in moderate physical activity to improve cardiovascular health and maintain a healthy weight.

    Monitoring and Follow-Up
    Regular Check-Ups:

    Frequent monitoring of kidney function (e.g., serum creatinine, GFR) and other relevant parameters.
    Regular visits to a nephrologist for specialized care.
    Monitoring for Complications:

    Keeping an eye on signs of worsening kidney function or complications such as fluid overload, electrolyte imbalances, and heart disease.
    Advanced Treatments
    Dialysis:

    Hemodialysis or peritoneal dialysis for advanced CKD when the kidneys can no longer function adequately on their own.
    Kidney Transplant:

    Considering kidney transplantation as a long-term solution for end-stage renal disease (ESRD).
    Education and Support
    Patient Education:

    Providing information on CKD and its management to empower patients to take an active role in their care.
    Educating about the importance of medication adherence and lifestyle changes.
    Support Groups:

    Encouraging participation in support groups for emotional and psychological support.

    Preventive Measures
    Screening for At-Risk Populations:

    Regular screening for individuals with risk factors such as diabetes, hypertension, and family history of kidney disease.
    Early Detection and Intervention:

    Early identification of CKD through routine health checks to initiate timely management and prevent progression.
    Combining these approaches can help manage CKD effectively, improve quality of life, and delay the progression to more advanced stages of the disease. It is essential for patients to work closely with their healthcare providers to tailor a management plan specific to their individual needs and conditions.
    Click Here for More Information: https://tinyurl.com/bd42n8a7

    #kidneydisease #solution #kidneyfunction #CholesterolManagement #bloodsugarcontrol
    Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. While there's no cure for CKD, management and treatment strategies aim to slow its progression, manage symptoms, and reduce complications. Here are some comprehensive strategies and approaches for managing CKD: Medical Management Blood Pressure Control: Use of antihypertensive medications such as ACE inhibitors or ARBs, which can also protect kidney function. Regular monitoring and maintaining blood pressure within target ranges. Blood Sugar Control (for Diabetic Patients): Tight control of blood glucose levels to prevent further kidney damage. Use of medications like SGLT2 inhibitors and GLP-1 receptor agonists that have renal benefits. Cholesterol Management: Use of statins or other lipid-lowering agents to reduce cardiovascular risk. Anemia Management: Use of erythropoiesis-stimulating agents (ESAs) and iron supplements to manage anemia commonly associated with CKD. Phosphate and Calcium Balance: Use of phosphate binders and vitamin D supplements to maintain bone health and prevent mineral and bone disorder in CKD. Lifestyle Modifications Dietary Adjustments: Low-sodium diet to help control blood pressure. Low-protein diet to reduce the kidneys' workload. Avoiding high-phosphorus foods to prevent mineral imbalance. Maintaining a healthy weight through balanced nutrition. Fluid Management: Proper hydration while avoiding overconsumption of fluids to prevent swelling and high blood pressure. Smoking Cessation: Quitting smoking to improve overall cardiovascular health and reduce further kidney damage. Regular Exercise: Engaging in moderate physical activity to improve cardiovascular health and maintain a healthy weight. Monitoring and Follow-Up Regular Check-Ups: Frequent monitoring of kidney function (e.g., serum creatinine, GFR) and other relevant parameters. Regular visits to a nephrologist for specialized care. Monitoring for Complications: Keeping an eye on signs of worsening kidney function or complications such as fluid overload, electrolyte imbalances, and heart disease. Advanced Treatments Dialysis: Hemodialysis or peritoneal dialysis for advanced CKD when the kidneys can no longer function adequately on their own. Kidney Transplant: Considering kidney transplantation as a long-term solution for end-stage renal disease (ESRD). Education and Support Patient Education: Providing information on CKD and its management to empower patients to take an active role in their care. Educating about the importance of medication adherence and lifestyle changes. Support Groups: Encouraging participation in support groups for emotional and psychological support. Preventive Measures Screening for At-Risk Populations: Regular screening for individuals with risk factors such as diabetes, hypertension, and family history of kidney disease. Early Detection and Intervention: Early identification of CKD through routine health checks to initiate timely management and prevent progression. Combining these approaches can help manage CKD effectively, improve quality of life, and delay the progression to more advanced stages of the disease. It is essential for patients to work closely with their healthcare providers to tailor a management plan specific to their individual needs and conditions. Click Here for More Information: https://tinyurl.com/bd42n8a7 #kidneydisease #solution #kidneyfunction #CholesterolManagement #bloodsugarcontrol
    0 Comments 0 Shares 8997 Views
  • Explore this fully customizable mental health education PowerPoint template to promote education programs and informal strategies for mental health. You can use this PPT template to help people maintain good health, behaviour, and inner motivation. Explore Now: https://bit.ly/4aw2Ghc
    #mentalhealth #mentalhealthawareness #mentalhealthtips #powerpointpresentation #presentation #ppt
    Explore this fully customizable mental health education PowerPoint template to promote education programs and informal strategies for mental health. You can use this PPT template to help people maintain good health, behaviour, and inner motivation. Explore Now: https://bit.ly/4aw2Ghc #mentalhealth #mentalhealthawareness #mentalhealthtips #powerpointpresentation #presentation #ppt
    BIT.LY
    Mental Health Education PowerPoint Template | PPT Templates
    Features: No. of slides - 01 Widescreen 16:9 You can change the color of the icons You can change the size, color and orientation of the shape Replace the text as per your need Replace an image as per your requirement
    0 Comments 0 Shares 3540 Views
  • An Educational Panel led by SSG Katie Thigpen featured SSgt. Katie Franke, Zenas Kim-Banther, and John Gruber on the topic of “What I Wish I’d Learned in School” at The U.S. Army Band 2024 American Trombone Workshop. #EducationalPanel #Education #ArmyMusic #MarineMusic #OberlinCollege #Oberlin #Trombone #ATW2024 #ATW #Music
    An Educational Panel led by SSG Katie Thigpen featured SSgt. Katie Franke, Zenas Kim-Banther, and John Gruber on the topic of “What I Wish I’d Learned in School” at The U.S. Army Band 2024 American Trombone Workshop. #EducationalPanel #Education #ArmyMusic #MarineMusic #OberlinCollege #Oberlin #Trombone #ATW2024 #ATW #Music
    0 Comments 0 Shares 2699 Views
  • Pfizer partnering with Ido Bachelet on DNA nanorobots
    OUTRAGED HUMAN
    “No, no it’s not science fiction; it’s already happening,” said Ido Bachelet to a somewhat incredulous audience member








    https://www.youtube.com/watch?v=MzLTWU2EqP4 Ido Bachelet - Moonshot Thinking


    ... when they cause too much damage by mistake...

    or intentionally...


    5:12

    study your biology and activate targeted medication when necessary.


    5:36

    We also know how to remote-control these robots, using magnetic fields.

    5:40

    Furthermore, we can control them, as you saw in the clip, with a joystick,

    5:43

    directing them to a specific part of the body,

    5:46

    and then activating them with the push of a button.

    5:49

    We have also connected this joystick to the internet.

    5:51

    Our robots have a IP address,

    5:54

    so you can connect with them from afar and activate them online.



    6:01

    Imagine that in a couple of years,

    6:03

    your doctor will be able to sit at home with his smartphone,

    6:05

    and instead of playing "Candy Crush"

    6:08

    he will connect with the robots inside of you,

    6:11

    activate a certain medication and possibly even save you, just in time.

    AND IMAGINE THAT YOU WOULDN'T EVEN KNOW IT, YOU WOULDN'T BE TOLD ABOUT IT.

    AND THAT IN ORDER TO IMPLANT/INJECT IT, YOU WOULD BE TOLD THAT THERE IS A DREADFUL PANDEMIC, AND AT EVERY STEP YOU WOULD BE FORCED TO TAKE IT AS A NECESSARY "VACCINATION." AND A “PCR TEST”.

    BY YOUR GOVERNMENT, THE AIRLINES, THE EMPLOYER, THE WAITER AT THE RESTAURANT, THE FDA, THE EMA, THE WORLD HEALTH ORGANIZATION...

    AND YET IMAGINE THAT MANY PEOPLE WOULD DIE FROM IT, AND THEY WOULD BE YOUR RELATIVES AND FRIENDS.

    BUT YOU WOULD BE THE ONE WHO WOULD HAVE TO PROVE THAT IT WAS BECAUSE OF IT.

    IMAGINE BEING SURROUNDED BY CENSORSHIP, BEING RIDICULED, HAVING YOUR RIGHTS TO DO YOUR JOB, MOVE AROUND, OR EVEN SPEAK THE TRUTH AT ALL TAKEN AWAY FROM YOU....

    ISN’T THIS A BRIGHT FURTURE AND A FANTASTIC REALITY?

    ARE YOU AGAINST SCIENCE? AGAINST PROGRESS? AGAINST PREVENTING DISEASES?



    https://www.nextbigfuture.com/2015/05/pfizer-partnering-with-ido-bachelet-on.html

    Pfizer is cooperating with the DNA robot laboratory managed by Prof. Ido Bachelet at Bar-Ilan University. Bachelet has developed a method of producing innovative DNA molecules with characteristics that can be used to "program" them to reach specific locations in the body and carry out pre-programmed operations there in response to stimulation from the body. This cooperation was revealed in a lecture by Pfizer president of worldwide research and development (WRD), portfolio strategy and investment committee chairman, and executive VP Mikael Dolstein at the IATI Biomed Conference in Tel Aviv being concluded today.

    Research will focus on the possibility that the robots will deliver the medical proteins to designated tissue.

    Bachelet came to Bar-Ilan from the Massachusetts Institute of Technology (MIT) several years ago. At a Tedmed event held two years ago, he explained, "In order to make a nanometric robot, we first of all create a selected DNA sequence, and then fold it using a process called DNA origami. With this method, a person can give a command to a computer, which folds the DNA molecule as needed.

    "The result is that a DNA sequence can be made in the form of a clam, for example, and containing a drug. The DNA molecule, however, contains a code activated upon encountering certain materials in the body. For example, the clam can be designed to change its shape and release the drug only when it meets a cancer cell or the right tissue.

    "In addition, the molecules can receive signals from each other, and can theoretically change their shape according to signals from the body, and can be pre-programmed to attach themselves to one another. In the future, it will be possible to combine each such molecule with a miniature antenna. When the antenna receives an external signal, it will make a small change in the molecule that will make it open or close, and dissipate or connect itself to another molecule."



    In a brief talk, Bachelet said DNA nanobots will soon be tried in a critically ill leukemia patient. The patient, who has been given roughly six months to live, will receive an injection of DNA nanobots designed to interact with and destroy leukemia cells—while causing virtually zero collateral damage in healthy tissue.

    According to Bachelet, his team have successfully tested their method in cell cultures and animals and written two papers on the subject, one in Science and one in Nature.

    Contemporary cancer therapies involving invasive surgery and blasts of drugs can be as painful and damaging to the body as the disease itself. If Bachelet's approach proves successful in humans, and is backed by more research in the coming years, the team’s work could signal a transformational moment in cancer treatment.

    If this treatment works this will be a medical breakthrough and can be used for many other diseases by delivering drugs more effectively without causing side effects.

    2012 Video with answers from George Church, Ido Bachelet and Shawn Douglas on the medical DNA double helix clamshell nanobucket nanobot



    George Church indicates the smart DNA nanobot has applications beyond nanomedicine. Applications where there is any need for programmable and targeted release or interaction at the cellular or near molecular scale.

    2014 Geek Time Presentation from Ido Bachelet



    “AND THE LAST THING I AM GOING TO SCHOW YOU IS… PANDEMIC.

    SO, WE ARE REALLY CONCERNED ABOUT PANDEMICS… ESPECIALLY INFLUENZA PANDEMICS.

    SO THE BEST WAY TO AVOID PANDEMICS OR TO HANDLE PANDEMICS, IS SIMPLY TO KNOW WHERE THE VIRUS IS AND NOT TO BE THERE…

    IT SOUNDS STUPID, BUT IT IS ACTUALLY THE CASE…

    IF YOU COULD IDENTIFY WHERE THE VIRUS IS IN REAL TIME AND YOU CAN CONTAIN THAT AREA, YOU WOULD STOP THE PANDEMIC, YOU WOULD STOP THE DISEASE… OK?


    SO, WHAT WE DEVELOPED IS A SENSOR… COMPOSED OF CARBON NANOTUBES FUNCTIONALIZED WITH ALL KIND OF THINGS… THE SENSOR IS EXTREMELY SENSITIVE… WE’VE BUILT THIS APPLICATION… THEY SEND THEIR GPS COORDINATES TO OUR SERVER SO WE CAN SORT OF RECONSTRUCT A REAL MAP…

    I HOPE YOU ENJOYED THIS AND UNDESTOOND WHAT BIONICS IS ALL ABOUT…

    At the British Friends of Bar-Ilan University's event in Otto Uomo October 2014 Professor Ido Bachelet announced the beginning of the human treatment with nanomedicine. He indicates DNA nanobots can currently identify cells in humans with 12 different types of cancer tumors.

    A human patient with late stage leukemia will be given DNA nanobot treatment. Without the DNA nanobot treatment the patient would be expected to die in the summer of 2015. Based upon animal trials they expect to remove the cancer within one month.

    Within 1 or 2 years they hope to have spinal cord repair working in animals and then shortly thereafter in humans. This is working in tissue cultures.

    Previously Ido Bachelet and Shawn Douglas have published work on DNA nanobots in the journal Nature and other respected science publications.

    One Trillion 50 nanometer nanobots in a syringe will be injected into people to perform cellular surgery.

    The DNA nanobots have been tuned to not cause an immune response.
    They have been adjusted for different kinds of medical procedures. Procedures can be quick or ones that last many days.


    Medicine or treatment released based upon molecular sensing - Only targeted cells are treated

    Ido's daughter has a leg disease which requires frequent surgery. He is hoping his DNA nanobots will make the type of surgery she needs relatively trivial - a simple injection at a doctor's office.

    We can control powerful drugs that were already developed

    Effective drugs that were withdrawn from the market for excessive toxicity can be combined with DNA nanobots for effective delivery. The tiny molecular computers of the DNA nanobots can provide molecular selective control for powerful medicines that were already developed.

    Using DNA origami and molecular programming, they are reality. These nanobots can seek and kill cancer cells, mimic social insect behaviors, carry out logical operators like a computer in a living animal, and they can be controlled from an Xbox. Ido Bachelet from the bio-design lab at Bar Ilan University explains this technology and how it will change medicine in the near future.

    Ido Bachelet earned his Ph.D. from the Hebrew University in Jerusalem, and was a postdoctoral fellow at M.I.T. and Harvard University. He is currently an assistant professor in the Faculty of Life Sciences and the Nano-Center at Bar Ilan University, Israel, the founder of several biotech companies, and a composer of music for piano and molecules.


    Researchers have injected various kinds of DNA nanobots into cockroaches. Because the nanobots are labelled with fluorescent markers, the researchers can follow them and analyse how different robot combinations affect where substances are delivered. The team says the accuracy of delivery and control of the nanobots is equivalent to a computer system.

    This is the development of the vision of nanomedicine.
    This is the realization of the power of DNA nanotechnology.
    This is programmable dna nanotechnology.

    The DNA nanotechnology cannot perform atomically precise chemistry (yet), but having control of the DNA combined with advanced synthetic biology and control of proteins and nanoparticles is clearly developing into very interesting capabilities.

    "This is the first time that biological therapy has been able to match how a computer processor works," says co-author Ido Bachelet of the Institute of Nanotechnology and Advanced Materials at Bar Ilan University.

    The team says it should be possible to scale up the computing power in the cockroach to that of an 8-bit computer, equivalent to a Commodore 64 or Atari 800 from the 1980s. Goni-Moreno agrees that this is feasible. "The mechanism seems easy to scale up so the complexity of the computations will soon become higher," he says.

    An obvious benefit of this technology would be cancer treatments, because these must be cell-specific and current treatments are not well-targeted. But a treatment like this in mammals must overcome the immune response triggered when a foreign object enters the body.

    Bachelet is confident that the team can enhance the robots' stability so that they can survive in mammals. "There is no reason why preliminary trials on humans can't start within five years," he says

    Biological systems are collections of discrete molecular objects that move around and collide with each other. Cells carry out elaborate processes by precisely controlling these collisions, but developing artificial machines that can interface with and control such interactions remains a significant challenge. DNA is a natural substrate for computing and has been used to implement a diverse set of mathematical problems, logic circuits and robotics. The molecule also interfaces naturally with living systems, and different forms of DNA-based biocomputing have already been demonstrated. Here, we show that DNA origami can be used to fabricate nanoscale robots that are capable of dynamically interacting with each other in a living animal. The interactions generate logical outputs, which are relayed to switch molecular payloads on or off. As a proof of principle, we use the system to create architectures that emulate various logic gates (AND, OR, XOR, NAND, NOT, CNOT and a half adder). Following an ex vivo prototyping phase, we successfully used the DNA origami robots in living cockroaches (Blaberus discoidalis) to control a molecule that targets their cells.

    Nature Nanotechnology - Universal computing by DNA origami robots in a living animal


    44 pages of supplemental information

    Ido Bachelet's moonshot to use nanorobotics for surgery has the potential to change lives globally. But who is the man behind the moonshot?

    Ido graduated from the Hebrew University of Jerusalem with a PhD in pharmacology and experimental therapeutics. Afterwards he did two postdocs; one in engineering at MIT and one in synthetic biology in the lab of George Church at the Wyss Institute at Harvard.

    Now, his group at Bar-Ilan University designs and studies diverse technologies inspired by nature.

    They will deliver enzymes that break down cells via programmable nanoparticles.
    Delivering insulin to tell cells to grow and regenerate tissue at the desired location.
    Surgery would be performed by putting the programmable nanoparticles into saline and injecting them into the body to seek out remove bad cells and grow new cells and perform other medical work.


    Research group website is here.












    SOLVE FOR DISEASE X?

    https://en.globes.co.il/en/article-pfizer-to-collaborate-on-bar-ilan-dna-robots-1001036703


    Pfizer is cooperating with the DNA robot laboratory managed by Prof. Ido Bachelet at Bar-Ilan University. Bachelet has developed a method of producing innovative DNA molecules with characteristics that can be used to "program" them to reach specific locations in the body and carry out pre-programmed operations there in response to stimulation from the body. This cooperation was revealed in a lecture by Pfizer president of worldwide research and development (WRD), portfolio strategy and investment committee chairman, and executive VP Mikael Dolstein at the IATI Biomed Conference in Tel Aviv being concluded today.

    Bar-Ilan Research & Development Co. CEO Orli Tori said, "This is Pfizer's first cooperative venture with someone in Israeli higher education. The technology is fairly new for a drug company, but Pfizer has agreed to take up the challenge and support this technology, in the hope that it will make a contribution to the company at the proper time.

    "As in all of our research agreements, the company coming from the industry has the right to negotiate the acquisition of the technology at the end of the process." The financial volume of the deal was not disclosed, but most such agreements amount to several hundred thousand dollars at most. The medical sector in which cooperation will take place was also not disclosed,

    but it appears that research will focus on the possibility that the robots will deliver the medical proteins to designated tissue.

    Bachelet came to Bar-Ilan from the Massachusetts Institute of Technology (MIT) several years ago. At a Tedmed event held two years ago, he explained, "In order to make a nanometric robot, we first of all create a selected DNA sequence, and then fold it using a process called DNA origami. With this method, a person can give a command to a computer, which folds the DNA molecule as needed.

    "The result is that a DNA sequence can be made in the form of a clam, for example, and containing a drug. The DNA molecule, however, contains a code activated upon encountering certain materials in the body. For example, the clam can be designed to change its shape and release the drug only when it meets a cancer cell or the right tissue.

    "In addition, the molecules can receive signals from each other, and can theoretically change their shape according to signals from the body, and can be pre-programmed to attach themselves to one another. In the future, it will be possible to combine each such molecule with a miniature antenna.

    When the antenna receives an external signal, it will make a small change in the molecule that will make it open or close, and dissipate or connect itself to another molecule."

    Tori adds, "What is special about the robots is that they open and close according to signals from the surroundings, and that makes it possible to manage the disease. The robot exposes the drug to the target site according to biological signs within the body. For example were we to develop a product for diabetes, although that is not the purpose of this cooperation, it would be possible to develop a robot that would release insulin only when it sensed a rise in the blood sugar level."

    Published by Globes [online], Israel business news - www.globes-online.com - on May 14, 2015

    https://www.nextbigfuture.com/2015/03/ido-bachelet-dna-nanobots-summary-with.html

    Disadvantages

    1. Designing of nanorobot is very costly and complicated

    2. Stray field might be created from electrical systems which can trigger bioelectric based molecular recognition system in biology

    3. Electrical nanorobots remain vulnerable to electrical interference from other sources like radiofrequency or electric fields, electromagnetic pulse and stray fields from other in-vivo electronic devices.

    4. Nanorobots are difficult to design, and customize

    5. These are capable of molecular level destruction of human body thus it can cause terrible effect in terrorism field. Terrorist may make usage of nanorobots as a tool for torturing opponent community

    6. Other possible threat associated with nanorobots is privacy issue.

    As it dealt with designing of miniature form of devices, there are risks for snooping than that exist already.

    [https://web.archive.org/web/20200718043030/https://pharmascope.org/ijrps/article/download/2523/5031]

    [https://web.archive.org/web/20150911233849/http://www.nanosafe.org/home/liblocal/docs/Nanosafe%202014/Session%201/PL1%20-%20Fran%C3%A7ois%20TARDIF.pdf]

    NANOROBOTS:

    SOCIETAL CONCERNS: INDIVIDUAL FREEDOM, TRANSHUMANISM!!!

    http://immortality-roadmap.com/nanorisk.pdf










    http://jddtonline.info/index.php/jddt/article/download/891/533

    There are several drawbacks with this technology like toxicity, contamination. Sometime human body generates strong immune response against them.

    https://web.archive.org/web/20051218111931/http://teknologiskfremsyn.dk:80/download/58.pdf


    “Nanotubes can be highly toxic”

    Fifteen percent of the rats treated with carbon nanotubes suffocated to death within twenty-four hours due to clumping of the nanotubes that obstructed the bronchial passageways.








    Toxicity- the issue of toxicity of nanoparticles was raised as an area in which more research is needed, particularly in terms of whether the regulatory system is sufficient.






    And it's injected into people, soldiers, children, even infants…

    Thank you Zz for this link.



    Pfizer partnering with Ido Bachelet on DNA nano robots.

    “No, no it’s not science fiction; it’s already happening,” said Ido Bachelet to a somewhat incredulous audience member, displaying a test tube in which he says just one drop contains approximately 1,000 billiard robots.

    https://outraged.substack.com/p/pfizer-partnering-with-ido-bachelet?utm_source=cross-post&publication_id=1087020&post_id=143153580&utm_campaign=956088&isFreemail=true&r=1sq9d8&triedRedirect=true&utm_medium=email

    Follow @zeeemedia
    Website | X | Instagram | Rumble

    https://telegra.ph/Pfizer-partnering-with-Ido-Bachelet-on-DNA-nanorobots-04-03
    Pfizer partnering with Ido Bachelet on DNA nanorobots OUTRAGED HUMAN “No, no it’s not science fiction; it’s already happening,” said Ido Bachelet to a somewhat incredulous audience member https://www.youtube.com/watch?v=MzLTWU2EqP4 Ido Bachelet - Moonshot Thinking ... when they cause too much damage by mistake... or intentionally... 5:12 study your biology and activate targeted medication when necessary. 5:36 We also know how to remote-control these robots, using magnetic fields. 5:40 Furthermore, we can control them, as you saw in the clip, with a joystick, 5:43 directing them to a specific part of the body, 5:46 and then activating them with the push of a button. 5:49 We have also connected this joystick to the internet. 5:51 Our robots have a IP address, 5:54 so you can connect with them from afar and activate them online. 6:01 Imagine that in a couple of years, 6:03 your doctor will be able to sit at home with his smartphone, 6:05 and instead of playing "Candy Crush" 6:08 he will connect with the robots inside of you, 6:11 activate a certain medication and possibly even save you, just in time. AND IMAGINE THAT YOU WOULDN'T EVEN KNOW IT, YOU WOULDN'T BE TOLD ABOUT IT. AND THAT IN ORDER TO IMPLANT/INJECT IT, YOU WOULD BE TOLD THAT THERE IS A DREADFUL PANDEMIC, AND AT EVERY STEP YOU WOULD BE FORCED TO TAKE IT AS A NECESSARY "VACCINATION." AND A “PCR TEST”. BY YOUR GOVERNMENT, THE AIRLINES, THE EMPLOYER, THE WAITER AT THE RESTAURANT, THE FDA, THE EMA, THE WORLD HEALTH ORGANIZATION... AND YET IMAGINE THAT MANY PEOPLE WOULD DIE FROM IT, AND THEY WOULD BE YOUR RELATIVES AND FRIENDS. BUT YOU WOULD BE THE ONE WHO WOULD HAVE TO PROVE THAT IT WAS BECAUSE OF IT. IMAGINE BEING SURROUNDED BY CENSORSHIP, BEING RIDICULED, HAVING YOUR RIGHTS TO DO YOUR JOB, MOVE AROUND, OR EVEN SPEAK THE TRUTH AT ALL TAKEN AWAY FROM YOU.... ISN’T THIS A BRIGHT FURTURE AND A FANTASTIC REALITY? ARE YOU AGAINST SCIENCE? AGAINST PROGRESS? AGAINST PREVENTING DISEASES? https://www.nextbigfuture.com/2015/05/pfizer-partnering-with-ido-bachelet-on.html Pfizer is cooperating with the DNA robot laboratory managed by Prof. Ido Bachelet at Bar-Ilan University. Bachelet has developed a method of producing innovative DNA molecules with characteristics that can be used to "program" them to reach specific locations in the body and carry out pre-programmed operations there in response to stimulation from the body. This cooperation was revealed in a lecture by Pfizer president of worldwide research and development (WRD), portfolio strategy and investment committee chairman, and executive VP Mikael Dolstein at the IATI Biomed Conference in Tel Aviv being concluded today. Research will focus on the possibility that the robots will deliver the medical proteins to designated tissue. Bachelet came to Bar-Ilan from the Massachusetts Institute of Technology (MIT) several years ago. At a Tedmed event held two years ago, he explained, "In order to make a nanometric robot, we first of all create a selected DNA sequence, and then fold it using a process called DNA origami. With this method, a person can give a command to a computer, which folds the DNA molecule as needed. "The result is that a DNA sequence can be made in the form of a clam, for example, and containing a drug. The DNA molecule, however, contains a code activated upon encountering certain materials in the body. For example, the clam can be designed to change its shape and release the drug only when it meets a cancer cell or the right tissue. "In addition, the molecules can receive signals from each other, and can theoretically change their shape according to signals from the body, and can be pre-programmed to attach themselves to one another. In the future, it will be possible to combine each such molecule with a miniature antenna. When the antenna receives an external signal, it will make a small change in the molecule that will make it open or close, and dissipate or connect itself to another molecule." In a brief talk, Bachelet said DNA nanobots will soon be tried in a critically ill leukemia patient. The patient, who has been given roughly six months to live, will receive an injection of DNA nanobots designed to interact with and destroy leukemia cells—while causing virtually zero collateral damage in healthy tissue. According to Bachelet, his team have successfully tested their method in cell cultures and animals and written two papers on the subject, one in Science and one in Nature. Contemporary cancer therapies involving invasive surgery and blasts of drugs can be as painful and damaging to the body as the disease itself. If Bachelet's approach proves successful in humans, and is backed by more research in the coming years, the team’s work could signal a transformational moment in cancer treatment. If this treatment works this will be a medical breakthrough and can be used for many other diseases by delivering drugs more effectively without causing side effects. 2012 Video with answers from George Church, Ido Bachelet and Shawn Douglas on the medical DNA double helix clamshell nanobucket nanobot George Church indicates the smart DNA nanobot has applications beyond nanomedicine. Applications where there is any need for programmable and targeted release or interaction at the cellular or near molecular scale. 2014 Geek Time Presentation from Ido Bachelet “AND THE LAST THING I AM GOING TO SCHOW YOU IS… PANDEMIC. SO, WE ARE REALLY CONCERNED ABOUT PANDEMICS… ESPECIALLY INFLUENZA PANDEMICS. SO THE BEST WAY TO AVOID PANDEMICS OR TO HANDLE PANDEMICS, IS SIMPLY TO KNOW WHERE THE VIRUS IS AND NOT TO BE THERE… IT SOUNDS STUPID, BUT IT IS ACTUALLY THE CASE… IF YOU COULD IDENTIFY WHERE THE VIRUS IS IN REAL TIME AND YOU CAN CONTAIN THAT AREA, YOU WOULD STOP THE PANDEMIC, YOU WOULD STOP THE DISEASE… OK? SO, WHAT WE DEVELOPED IS A SENSOR… COMPOSED OF CARBON NANOTUBES FUNCTIONALIZED WITH ALL KIND OF THINGS… THE SENSOR IS EXTREMELY SENSITIVE… WE’VE BUILT THIS APPLICATION… THEY SEND THEIR GPS COORDINATES TO OUR SERVER SO WE CAN SORT OF RECONSTRUCT A REAL MAP… I HOPE YOU ENJOYED THIS AND UNDESTOOND WHAT BIONICS IS ALL ABOUT… At the British Friends of Bar-Ilan University's event in Otto Uomo October 2014 Professor Ido Bachelet announced the beginning of the human treatment with nanomedicine. He indicates DNA nanobots can currently identify cells in humans with 12 different types of cancer tumors. A human patient with late stage leukemia will be given DNA nanobot treatment. Without the DNA nanobot treatment the patient would be expected to die in the summer of 2015. Based upon animal trials they expect to remove the cancer within one month. Within 1 or 2 years they hope to have spinal cord repair working in animals and then shortly thereafter in humans. This is working in tissue cultures. Previously Ido Bachelet and Shawn Douglas have published work on DNA nanobots in the journal Nature and other respected science publications. One Trillion 50 nanometer nanobots in a syringe will be injected into people to perform cellular surgery. The DNA nanobots have been tuned to not cause an immune response. They have been adjusted for different kinds of medical procedures. Procedures can be quick or ones that last many days. Medicine or treatment released based upon molecular sensing - Only targeted cells are treated Ido's daughter has a leg disease which requires frequent surgery. He is hoping his DNA nanobots will make the type of surgery she needs relatively trivial - a simple injection at a doctor's office. We can control powerful drugs that were already developed Effective drugs that were withdrawn from the market for excessive toxicity can be combined with DNA nanobots for effective delivery. The tiny molecular computers of the DNA nanobots can provide molecular selective control for powerful medicines that were already developed. Using DNA origami and molecular programming, they are reality. These nanobots can seek and kill cancer cells, mimic social insect behaviors, carry out logical operators like a computer in a living animal, and they can be controlled from an Xbox. Ido Bachelet from the bio-design lab at Bar Ilan University explains this technology and how it will change medicine in the near future. Ido Bachelet earned his Ph.D. from the Hebrew University in Jerusalem, and was a postdoctoral fellow at M.I.T. and Harvard University. He is currently an assistant professor in the Faculty of Life Sciences and the Nano-Center at Bar Ilan University, Israel, the founder of several biotech companies, and a composer of music for piano and molecules. Researchers have injected various kinds of DNA nanobots into cockroaches. Because the nanobots are labelled with fluorescent markers, the researchers can follow them and analyse how different robot combinations affect where substances are delivered. The team says the accuracy of delivery and control of the nanobots is equivalent to a computer system. This is the development of the vision of nanomedicine. This is the realization of the power of DNA nanotechnology. This is programmable dna nanotechnology. The DNA nanotechnology cannot perform atomically precise chemistry (yet), but having control of the DNA combined with advanced synthetic biology and control of proteins and nanoparticles is clearly developing into very interesting capabilities. "This is the first time that biological therapy has been able to match how a computer processor works," says co-author Ido Bachelet of the Institute of Nanotechnology and Advanced Materials at Bar Ilan University. The team says it should be possible to scale up the computing power in the cockroach to that of an 8-bit computer, equivalent to a Commodore 64 or Atari 800 from the 1980s. Goni-Moreno agrees that this is feasible. "The mechanism seems easy to scale up so the complexity of the computations will soon become higher," he says. An obvious benefit of this technology would be cancer treatments, because these must be cell-specific and current treatments are not well-targeted. But a treatment like this in mammals must overcome the immune response triggered when a foreign object enters the body. Bachelet is confident that the team can enhance the robots' stability so that they can survive in mammals. "There is no reason why preliminary trials on humans can't start within five years," he says Biological systems are collections of discrete molecular objects that move around and collide with each other. Cells carry out elaborate processes by precisely controlling these collisions, but developing artificial machines that can interface with and control such interactions remains a significant challenge. DNA is a natural substrate for computing and has been used to implement a diverse set of mathematical problems, logic circuits and robotics. The molecule also interfaces naturally with living systems, and different forms of DNA-based biocomputing have already been demonstrated. Here, we show that DNA origami can be used to fabricate nanoscale robots that are capable of dynamically interacting with each other in a living animal. The interactions generate logical outputs, which are relayed to switch molecular payloads on or off. As a proof of principle, we use the system to create architectures that emulate various logic gates (AND, OR, XOR, NAND, NOT, CNOT and a half adder). Following an ex vivo prototyping phase, we successfully used the DNA origami robots in living cockroaches (Blaberus discoidalis) to control a molecule that targets their cells. Nature Nanotechnology - Universal computing by DNA origami robots in a living animal 44 pages of supplemental information Ido Bachelet's moonshot to use nanorobotics for surgery has the potential to change lives globally. But who is the man behind the moonshot? Ido graduated from the Hebrew University of Jerusalem with a PhD in pharmacology and experimental therapeutics. Afterwards he did two postdocs; one in engineering at MIT and one in synthetic biology in the lab of George Church at the Wyss Institute at Harvard. Now, his group at Bar-Ilan University designs and studies diverse technologies inspired by nature. They will deliver enzymes that break down cells via programmable nanoparticles. Delivering insulin to tell cells to grow and regenerate tissue at the desired location. Surgery would be performed by putting the programmable nanoparticles into saline and injecting them into the body to seek out remove bad cells and grow new cells and perform other medical work. Research group website is here. SOLVE FOR DISEASE X? https://en.globes.co.il/en/article-pfizer-to-collaborate-on-bar-ilan-dna-robots-1001036703 Pfizer is cooperating with the DNA robot laboratory managed by Prof. Ido Bachelet at Bar-Ilan University. Bachelet has developed a method of producing innovative DNA molecules with characteristics that can be used to "program" them to reach specific locations in the body and carry out pre-programmed operations there in response to stimulation from the body. This cooperation was revealed in a lecture by Pfizer president of worldwide research and development (WRD), portfolio strategy and investment committee chairman, and executive VP Mikael Dolstein at the IATI Biomed Conference in Tel Aviv being concluded today. Bar-Ilan Research & Development Co. CEO Orli Tori said, "This is Pfizer's first cooperative venture with someone in Israeli higher education. The technology is fairly new for a drug company, but Pfizer has agreed to take up the challenge and support this technology, in the hope that it will make a contribution to the company at the proper time. "As in all of our research agreements, the company coming from the industry has the right to negotiate the acquisition of the technology at the end of the process." The financial volume of the deal was not disclosed, but most such agreements amount to several hundred thousand dollars at most. The medical sector in which cooperation will take place was also not disclosed, but it appears that research will focus on the possibility that the robots will deliver the medical proteins to designated tissue. Bachelet came to Bar-Ilan from the Massachusetts Institute of Technology (MIT) several years ago. At a Tedmed event held two years ago, he explained, "In order to make a nanometric robot, we first of all create a selected DNA sequence, and then fold it using a process called DNA origami. With this method, a person can give a command to a computer, which folds the DNA molecule as needed. "The result is that a DNA sequence can be made in the form of a clam, for example, and containing a drug. The DNA molecule, however, contains a code activated upon encountering certain materials in the body. For example, the clam can be designed to change its shape and release the drug only when it meets a cancer cell or the right tissue. "In addition, the molecules can receive signals from each other, and can theoretically change their shape according to signals from the body, and can be pre-programmed to attach themselves to one another. In the future, it will be possible to combine each such molecule with a miniature antenna. When the antenna receives an external signal, it will make a small change in the molecule that will make it open or close, and dissipate or connect itself to another molecule." Tori adds, "What is special about the robots is that they open and close according to signals from the surroundings, and that makes it possible to manage the disease. The robot exposes the drug to the target site according to biological signs within the body. For example were we to develop a product for diabetes, although that is not the purpose of this cooperation, it would be possible to develop a robot that would release insulin only when it sensed a rise in the blood sugar level." Published by Globes [online], Israel business news - www.globes-online.com - on May 14, 2015 https://www.nextbigfuture.com/2015/03/ido-bachelet-dna-nanobots-summary-with.html Disadvantages 1. Designing of nanorobot is very costly and complicated 2. Stray field might be created from electrical systems which can trigger bioelectric based molecular recognition system in biology 3. Electrical nanorobots remain vulnerable to electrical interference from other sources like radiofrequency or electric fields, electromagnetic pulse and stray fields from other in-vivo electronic devices. 4. Nanorobots are difficult to design, and customize 5. These are capable of molecular level destruction of human body thus it can cause terrible effect in terrorism field. Terrorist may make usage of nanorobots as a tool for torturing opponent community 6. Other possible threat associated with nanorobots is privacy issue. As it dealt with designing of miniature form of devices, there are risks for snooping than that exist already. [https://web.archive.org/web/20200718043030/https://pharmascope.org/ijrps/article/download/2523/5031] [https://web.archive.org/web/20150911233849/http://www.nanosafe.org/home/liblocal/docs/Nanosafe%202014/Session%201/PL1%20-%20Fran%C3%A7ois%20TARDIF.pdf] NANOROBOTS: SOCIETAL CONCERNS: INDIVIDUAL FREEDOM, TRANSHUMANISM!!! http://immortality-roadmap.com/nanorisk.pdf http://jddtonline.info/index.php/jddt/article/download/891/533 There are several drawbacks with this technology like toxicity, contamination. Sometime human body generates strong immune response against them. https://web.archive.org/web/20051218111931/http://teknologiskfremsyn.dk:80/download/58.pdf “Nanotubes can be highly toxic” Fifteen percent of the rats treated with carbon nanotubes suffocated to death within twenty-four hours due to clumping of the nanotubes that obstructed the bronchial passageways. Toxicity- the issue of toxicity of nanoparticles was raised as an area in which more research is needed, particularly in terms of whether the regulatory system is sufficient. … And it's injected into people, soldiers, children, even infants… Thank you Zz for this link. Pfizer partnering with Ido Bachelet on DNA nano robots. “No, no it’s not science fiction; it’s already happening,” said Ido Bachelet to a somewhat incredulous audience member, displaying a test tube in which he says just one drop contains approximately 1,000 billiard robots. https://outraged.substack.com/p/pfizer-partnering-with-ido-bachelet?utm_source=cross-post&publication_id=1087020&post_id=143153580&utm_campaign=956088&isFreemail=true&r=1sq9d8&triedRedirect=true&utm_medium=email Follow @zeeemedia Website | X | Instagram | Rumble https://telegra.ph/Pfizer-partnering-with-Ido-Bachelet-on-DNA-nanorobots-04-03
    OUTRAGED.SUBSTACK.COM
    Pfizer partnering with Ido Bachelet on DNA nanorobots
    “No, no it’s not science fiction; it’s already happening,” said Ido Bachelet to a somewhat incredulous audience member Thanks for reading OUTRAGED’s Newsletter! Subscribe for free to receive new posts and support my work. https://www.youtube.com/watch?v=MzLTWU2EqP4
    Angry
    1
    0 Comments 0 Shares 56127 Views
  • CASE 01 - Autopsy proven myocarditis death in AUSTRALIA
    Barrack Heights NSW, AUSTRALIA - Roberto Garin was only 52 when he ‘died suddenly’ on 28 July 2021. The healthy father of two teenagers began feeling ill 48 hours after his first Pfizer shot and dropped dead in front of his terrified wife Kirsti six days later while she was on the phone to paramedics.
    Garin’s family immediately suspected the vaccine caused his death. Kirsti was told her husband was the first person to die after a Pfizer shot. In fact, 176 deaths following Pfizer jabs had already been reported to the Therapeutic Goods Administration (TGA), starting in the first week of the vaccine rollout.
    But when Kirsti shared her concerns with filmmaker Alan Hashem, who released the video together with the accounts of other vaccine injuries and deaths, it unleashed a storm.
    ‘Misinformation researchers’ published by the ABC dismissed Kirsti’s ‘claims her 52-year-old husband died from “sudden onset myocarditis” after receiving the Pfizer vaccine’ because it didn’t ‘square with official data’.
    Yet that was exactly what forensic pathologist Bernard l’Ons wrote in a brilliant report on his autopsy stating that the deceased’s heart showed a clear transition to severe giant cell myocarditis that could be ‘histologically dated to the time period of the Covid-19 mRNA vaccination’ and it was ‘reasonable to state that the deceased’s previously undiagnosed cardiac sarcoidosis may have transitioned to a fulminating myocarditis as a result of the Pfizer Covid-19 vaccination’ noting that myocarditis had been reported in reactions to the Pfizer vaccine. L’Ons proposed a mechanism by which the vaccine could trigger fatal myocarditis and advised that a possible therapeutic implication was that sarcoid patients be given an echocardiogram to detect whether their heart was affected in which case alternative vaccination types could be considered.
    All of this was ignored by the TGA which refuses to admit to this day that any death can be attributed to a Pfizer vaccine and was parroted by the ABC. The TGA did admit that as of 22 August it had received ‘235 reports of suspected myocarditis, (inflammation of the heart muscle) and/or pericarditis (inflammation of the membrane around the heart) following vaccination’ with Pfizer but said, ‘These reports reflect the observations of the people reporting them and have not been confirmed as having been caused by the vaccine,’ and that ‘some events may be coincidental and would have happened anyway, regardless of vaccination.’
    This is a particularly misleading statement. Four out of five reports to the TGA are submitted not by random ‘people’, but by highly qualified health professionals and in Garin’s case by a forensic pathologist.
    Why would the TGA dismiss these reports? That’s a question Associate Professor Michael Nissen could perhaps shed light on. He was appointed to the TGA in February 2021, just as the Covid-19 vaccines were rolled out, to lead its Signal Investigation Unit which investigates safety issues that arise with vaccines in adverse reports or are raised by international regulators or the medical literature.
    Prior to his appointment, Nissen was the Director of Scientific Affairs and Public Health at GSK Vaccines from October 2014 to January 2021, a period during which GSK and Pfizer entered into a joint venture. Nissen worked concurrently in hospital-based medical care and academia. He has led over 40 clinical trials and authored over 200 peer-reviewed publications including vaccine studies. In all these areas pharmaceutical companies are a major source of funding.
    The TGA is sensitive about managing conflicts of interest for advisory committee members but offers no guidance on its website with regard to staff members although presumably the same principles should, at least in theory, apply. It notes that shares, involvement in clinical trials, employment, contracts, consultancies, grants, sponsorships, board memberships and so on, may give rise to a conflict of interest.
    Robert Clancy, an Emeritus Professor of Pathology at the University of Newcastle Medical School and a member of the Australian Academy of Science’s Covid-19 Expert Database wrote in Quadrant online last week that ‘the power of the pharmaceutical industry and its pervasive influence at every level of political and medical decision-making’ has been underestimated in shaping the pandemic narrative which has been driven by commercial imperatives to such an extent that it has crushed scientific debate.
    Clancy recounts that his approach to the College of Pathology (of which he was a Senior Fellow, a foundation Professor of Pathology, and past-Chairman of the College committee for undergraduate pathology education) calling for a national study to determine whether Covid vaccination was responsible for the increase in excess mortality in Australia and elsewhere by developing a protocol for post-mortems ‘to answer what is arguably the most important question facing medicine’ met with a rejection and a suggestion to take it instead to the TGA.
    Nowadays, dying suddenly has become ominously familiar. According to a new film Died Suddenly available as of this week to stream via Twitter, in the last 18 months, the term ‘Died Suddenly’ has risen to the very top of ‘most searched’ Google terms. The film documents the surge in excess mortality in highly vaccinated countries. Dr. Peter McCullough, internist, cardiologist, epidemiologist, and one of the top five most-published, and most censored, medical researchers in the US, says that sudden death frequently occurs because the heart has been damaged by inflammation caused by Covid vaccines.
    Papers that Pfizer and the Food and Drug Administration tried to hide for 75 years show that Pfizer knew in 2020 that myocarditis and pericarditis could be caused by its vaccine.
    And in the Pfizer trial in Argentina, a report on a healthy 36-year old  participant – Augusto German Roux – who developed pericarditis immediately after his second Pfizer jab, mysteriously disappeared from the published trial results.
    The Australian Technical Advisory Group on Immunisation (ATAGI) and the Cardiac Society of Australia and New Zealand (CSANZ) belatedly published a warning about myocarditis and pericarditis in September this year.
    It was too late for Garin. Had his doctors known, his life might have been saved. His grieving family have still not received a cent in compensation. But Pfizer has apparently grossed nearly $100 billion from its sales of Covid-19 vaccines and treatments.
    Rebecca Weisser is an independent journalist.
    ======


    https://open.substack.com/pub/makismd/p/mrna-injury-stories-australian-dad?r=29hg4d&utm_medium=ios
    CASE 01 - Autopsy proven myocarditis death in AUSTRALIA Barrack Heights NSW, AUSTRALIA - Roberto Garin was only 52 when he ‘died suddenly’ on 28 July 2021. The healthy father of two teenagers began feeling ill 48 hours after his first Pfizer shot and dropped dead in front of his terrified wife Kirsti six days later while she was on the phone to paramedics. Garin’s family immediately suspected the vaccine caused his death. Kirsti was told her husband was the first person to die after a Pfizer shot. In fact, 176 deaths following Pfizer jabs had already been reported to the Therapeutic Goods Administration (TGA), starting in the first week of the vaccine rollout. But when Kirsti shared her concerns with filmmaker Alan Hashem, who released the video together with the accounts of other vaccine injuries and deaths, it unleashed a storm. ‘Misinformation researchers’ published by the ABC dismissed Kirsti’s ‘claims her 52-year-old husband died from “sudden onset myocarditis” after receiving the Pfizer vaccine’ because it didn’t ‘square with official data’. Yet that was exactly what forensic pathologist Bernard l’Ons wrote in a brilliant report on his autopsy stating that the deceased’s heart showed a clear transition to severe giant cell myocarditis that could be ‘histologically dated to the time period of the Covid-19 mRNA vaccination’ and it was ‘reasonable to state that the deceased’s previously undiagnosed cardiac sarcoidosis may have transitioned to a fulminating myocarditis as a result of the Pfizer Covid-19 vaccination’ noting that myocarditis had been reported in reactions to the Pfizer vaccine. L’Ons proposed a mechanism by which the vaccine could trigger fatal myocarditis and advised that a possible therapeutic implication was that sarcoid patients be given an echocardiogram to detect whether their heart was affected in which case alternative vaccination types could be considered. All of this was ignored by the TGA which refuses to admit to this day that any death can be attributed to a Pfizer vaccine and was parroted by the ABC. The TGA did admit that as of 22 August it had received ‘235 reports of suspected myocarditis, (inflammation of the heart muscle) and/or pericarditis (inflammation of the membrane around the heart) following vaccination’ with Pfizer but said, ‘These reports reflect the observations of the people reporting them and have not been confirmed as having been caused by the vaccine,’ and that ‘some events may be coincidental and would have happened anyway, regardless of vaccination.’ This is a particularly misleading statement. Four out of five reports to the TGA are submitted not by random ‘people’, but by highly qualified health professionals and in Garin’s case by a forensic pathologist. Why would the TGA dismiss these reports? That’s a question Associate Professor Michael Nissen could perhaps shed light on. He was appointed to the TGA in February 2021, just as the Covid-19 vaccines were rolled out, to lead its Signal Investigation Unit which investigates safety issues that arise with vaccines in adverse reports or are raised by international regulators or the medical literature. Prior to his appointment, Nissen was the Director of Scientific Affairs and Public Health at GSK Vaccines from October 2014 to January 2021, a period during which GSK and Pfizer entered into a joint venture. Nissen worked concurrently in hospital-based medical care and academia. He has led over 40 clinical trials and authored over 200 peer-reviewed publications including vaccine studies. In all these areas pharmaceutical companies are a major source of funding. The TGA is sensitive about managing conflicts of interest for advisory committee members but offers no guidance on its website with regard to staff members although presumably the same principles should, at least in theory, apply. It notes that shares, involvement in clinical trials, employment, contracts, consultancies, grants, sponsorships, board memberships and so on, may give rise to a conflict of interest. Robert Clancy, an Emeritus Professor of Pathology at the University of Newcastle Medical School and a member of the Australian Academy of Science’s Covid-19 Expert Database wrote in Quadrant online last week that ‘the power of the pharmaceutical industry and its pervasive influence at every level of political and medical decision-making’ has been underestimated in shaping the pandemic narrative which has been driven by commercial imperatives to such an extent that it has crushed scientific debate. Clancy recounts that his approach to the College of Pathology (of which he was a Senior Fellow, a foundation Professor of Pathology, and past-Chairman of the College committee for undergraduate pathology education) calling for a national study to determine whether Covid vaccination was responsible for the increase in excess mortality in Australia and elsewhere by developing a protocol for post-mortems ‘to answer what is arguably the most important question facing medicine’ met with a rejection and a suggestion to take it instead to the TGA. Nowadays, dying suddenly has become ominously familiar. According to a new film Died Suddenly available as of this week to stream via Twitter, in the last 18 months, the term ‘Died Suddenly’ has risen to the very top of ‘most searched’ Google terms. The film documents the surge in excess mortality in highly vaccinated countries. Dr. Peter McCullough, internist, cardiologist, epidemiologist, and one of the top five most-published, and most censored, medical researchers in the US, says that sudden death frequently occurs because the heart has been damaged by inflammation caused by Covid vaccines. Papers that Pfizer and the Food and Drug Administration tried to hide for 75 years show that Pfizer knew in 2020 that myocarditis and pericarditis could be caused by its vaccine. And in the Pfizer trial in Argentina, a report on a healthy 36-year old  participant – Augusto German Roux – who developed pericarditis immediately after his second Pfizer jab, mysteriously disappeared from the published trial results. The Australian Technical Advisory Group on Immunisation (ATAGI) and the Cardiac Society of Australia and New Zealand (CSANZ) belatedly published a warning about myocarditis and pericarditis in September this year. It was too late for Garin. Had his doctors known, his life might have been saved. His grieving family have still not received a cent in compensation. But Pfizer has apparently grossed nearly $100 billion from its sales of Covid-19 vaccines and treatments. Rebecca Weisser is an independent journalist. ====== https://open.substack.com/pub/makismd/p/mrna-injury-stories-australian-dad?r=29hg4d&utm_medium=ios
    Angry
    1
    0 Comments 1 Shares 26834 Views
  • The WHO Pandemic Agreement: A Guide
    By David Bell, Thi Thuy Van Dinh March 22, 2024 Government, Society 30 minute read
    The World Health Organization (WHO) and its 194 Member States have been engaged for over two years in the development of two ‘instruments’ or agreements with the intent of radically changing the way pandemics and other health emergencies are managed.

    One, consisting of draft amendments to the existing International health Regulations (IHR), seeks to change the current IHR non-binding recommendations into requirements or binding recommendations, by having countries “undertake” to implement those given by the WHO in future declared health emergencies. It covers all ‘public health emergencies of international concern’ (PHEIC), with a single person, the WHO Director-General (DG) determining what a PHEIC is, where it extends, and when it ends. It specifies mandated vaccines, border closures, and other directives understood as lockdowns among the requirements the DG can impose. It is discussed further elsewhere and still under negotiation in Geneva.

    A second document, previously known as the (draft) Pandemic Treaty, then Pandemic Accord, and more recently the Pandemic Agreement, seeks to specify governance, supply chains, and various other interventions aimed at preventing, preparing for, and responding to, pandemics (pandemic prevention, preparedness and response – PPPR). It is currently being negotiated by the Intergovernmental Negotiating Body (INB).

    Both texts will be subject to a vote at the May 2024 World Health Assembly (WHA) in Geneva, Switzerland. These votes are intended, by those promoting these projects, to bring governance of future multi-country healthcare emergencies (or threats thereof) under the WHO umbrella.

    The latest version of the draft Pandemic Agreement (here forth the ‘Agreement’) was released on 7th March 2024. However, it is still being negotiated by various committees comprising representatives of Member States and other interested entities. It has been through multiple iterations over two years, and looks like it. With the teeth of the pandemic response proposals in the IHR, the Agreement looks increasingly irrelevant, or at least unsure of its purpose, picking up bits and pieces in a half-hearted way that the IHR amendments do not, or cannot, include. However, as discussed below, it is far from irrelevant.

    Historical Perspective

    These aim to increase the centralization of decision-making within the WHO as the “directing and coordinating authority.” This terminology comes from the WHO’s 1946 Constitution, developed in the aftermath of the Second World War as the world faced the outcomes of European fascism and the similar approaches widely imposed through colonialist regimes. The WHO would support emerging countries, with rapidly expanding and poorly resourced populations struggling under high disease burdens, and coordinate some areas of international support as these sovereign countries requested it. The emphasis of action was on coordinating rather than directing.

    In the 80 years prior to the WHO’s existence, international public health had grown within a more directive mindset, with a series of meetings by colonial and slave-owning powers from 1851 to manage pandemics, culminating in the inauguration of the Office Internationale d’Hygiene Publique in Paris in 1907, and later the League of Nations Health Office. World powers imposed health dictates on those less powerful, in other parts of the world and increasingly on their own population through the eugenics movement and similar approaches. Public health would direct, for the greater good, as a tool of those who wish to direct the lives of others.

    The WHO, governed by the WHA, was to be very different. Newly independent States and their former colonial masters were ostensibly on an equal footing within the WHA (one country – one vote), and the WHO’s work overall was to be an example of how human rights could dominate the way society works. The model for international public health, as exemplified in the Declaration of Alma Ata in 1978, was to be horizontal rather than vertical, with communities and countries in the driving seat.

    With the evolution of the WHO in recent decades from a core funding model (countries give money, the WHO decides under the WHA guidance how to spend it) to a model based on specified funding (funders, both public and increasingly private, instruct the WHO on how to spend it), the WHO has inevitably changed to become a public-private partnership required to serve the interests of funders rather than populations.

    As most funding comes from a few countries with major Pharma industrial bases, or private investors and corporations in the same industry, the WHO has been required to emphasize the use of pharmaceuticals and downplay evidence and knowledge where these clash (if it wants to keep all its staff funded). It is helpful to view the draft Agreement, and the IHR amendments, in this context.

    Why May 2024?

    The WHO, together with the World Bank, G20, and other institutions have been emphasizing the urgency of putting the new pandemic instruments in place earnestly, before the ‘next pandemic.’ This is based on claims that the world was unprepared for Covid-19, and that the economic and health harm would be somehow avoidable if we had these agreements in place.

    They emphasize, contrary to evidence that Covid-19 virus (SARS-CoV-2) origins involve laboratory manipulation, that the main threats we face are natural, and that these are increasing exponentially and present an “existential” threat to humanity. The data on which the WHO, the World Bank, and G20 base these claims demonstrates the contrary, with reported natural outbreaks having increased as detection technologies have developed, but reducing in mortality rate, and in numbers, over the past 10 to 20 years..

    A paper cited by the World Bank to justify urgency and quoted as suggesting a 3x increase in risk in the coming decade actually suggests that a Covid-19-like event would occur roughly every 129 years, and a Spanish-flu repetition every 292 to 877 years. Such predictions are unable to take into account the rapidly changing nature of medicine and improved sanitation and nutrition (most deaths from Spanish flu would not have occurred if modern antibiotics had been available), and so may still overestimate risk. Similarly, the WHO’s own priority disease list for new outbreaks only includes two diseases of proven natural origin that have over 1,000 historical deaths attributed to them. It is well demonstrated that the risk and expected burden of pandemics is misrepresented by major international agencies in current discussions.

    The urgency for May 2024 is clearly therefore inadequately supported, firstly because neither the WHO nor others have demonstrated how the harms accrued through Covid-19 would be reduced through the measures proposed, and secondly because the burden and risk is misrepresented. In this context, the state of the Agreement is clearly not where it should be as a draft international legally binding agreement intended to impose considerable financial and other obligations on States and populations.

    This is particularly problematic as the proposed expenditure; the proposed budget is over $31 billion per year, with over $10 billion more on other One Health activities. Much of this will have to be diverted from addressing other diseases burdens that impose far greater burden. This trade-off, essential to understand in public health policy development, has not yet been clearly addressed by the WHO.

    The WHO DG stated recently that the WHO does not want the power to impose vaccine mandates or lockdowns on anyone, and does not want this. This begs the question of why either of the current WHO pandemic instruments is being proposed, both as legally binding documents. The current IHR (2005) already sets out such approaches as recommendations the DG can make, and there is nothing non-mandatory that countries cannot do now without pushing new treaty-like mechanisms through a vote in Geneva.

    Based on the DG’s claims, they are essentially redundant, and what new non-mandatory clauses they contain, as set out below, are certainly not urgent. Clauses that are mandatory (Member States “shall”) must be considered within national decision-making contexts and appear against the WHO’s stated intent.

    Common sense would suggest that the Agreement, and the accompanying IHR amendments, be properly thought through before Member States commit. The WHO has already abandoned the legal requirement for a 4-month review time for the IHR amendments (Article 55.2 IHR), which are also still under negotiation just 2 months before the WHA deadline. The Agreement should also have at least such a period for States to properly consider whether to agree – treaties normally take many years to develop and negotiate and no valid arguments have been put forward as to why these should be different.

    The Covid-19 response resulted in an unprecedented transfer of wealth from those of lower income to the very wealthy few, completely contrary to the way in which the WHO was intended to affect human society. A considerable portion of these pandemic profits went to current sponsors of the WHO, and these same corporate entities and investors are set to further benefit from the new pandemic agreements. As written, the Pandemic Agreement risks entrenching such centralization and profit-taking, and the accompanying unprecedented restrictions on human rights and freedoms, as a public health norm.

    To continue with a clearly flawed agreement simply because of a previously set deadline, when no clear population benefit is articulated and no true urgency demonstrated, would therefore be a major step backward in international public health. Basic principles of proportionality, human agency, and community empowerment, essential for health and human rights outcomes, are missing or paid lip-service. The WHO clearly wishes to increase its funding and show it is ‘doing something,’ but must first articulate why the voluntary provisions of the current IHR are insufficient. It is hoped that by systematically reviewing some key clauses of the agreement here, it will become clear why a rethink of the whole approach is necessary. The full text is found below.

    The commentary below concentrates on selected draft provisions of the latest publicly available version of the draft agreement that seem to be unclear or potentially problematic. Much of the remaining text is essentially pointless as it reiterates vague intentions to be found in other documents or activities which countries normally undertake in the course of running health services, and have no place in a focused legally-binding international agreement.

    REVISED Draft of the negotiating text of the WHO Pandemic Agreement. 7th March, 2024

    Preamble

    Recognizing that the World Health Organization…is the directing and coordinating authority on international health work.

    This is inconsistent with a recent statement by the WHO DG that the WHO has no interest or intent to direct country health responses. To reiterate it here suggests that the DG is not representing the true position regarding the Agreement. “Directing authority” is however in line with the proposed IHR Amendments (and the WHO’s Constitution), under which countries will “undertake” ahead of time to follow the DG’s recommendations (which thereby become instructions). As the HR amendments make clear, this is intended to apply even to a perceived threat rather than actual harm.

    Recalling the constitution of the World Health Organization…highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.

    This statement recalls fundamental understandings of public health, and is of importance here as it raises the question of why the WHO did not strongly condemn prolonged school closures, workplace closures, and other impoverishing policies during the Covid-19 response. In 2019, WHO made clear that these dangers should prevent actions we now call ‘lockdowns’ from being imposed.

    Deeply concerned by the gross inequities at national and international levels that hindered timely and equitable access to medical and other Covid-19 pandemic-related products, and the serious shortcomings in pandemic preparedness.

    In terms of health equity (as distinct from commodity of ‘vaccine’ equity), inequity in the Covid-19 response was not in failing to provide a vaccine against former variants to immune, young people in low-income countries who were at far higher risk from endemic diseases, but in the disproportionate harm to them of uniformly-imposed NPIs that reduced current and future income and basic healthcare, as was noted by the WHO in 2019 Pandemic Influenza recommendations. The failure of the text to recognize this suggests that lessons from Covid-19 have not informed this draft Agreement. The WHO has not yet demonstrated how pandemic ‘preparedness,’ in the terms they use below, would have reduced impact, given that there is poor correlation between strictness or speed of response and eventual outcomes.

    Reiterating the need to work towards…an equitable approach to mitigate the risk that pandemics exacerbate existing inequities in access to health services,

    As above – in the past century, the issue of inequity has been most pronounced in pandemic response, rather than the impact of the virus itself (excluding the physiological variation in risk). Most recorded deaths from acute pandemics, since the Spanish flu, were during Covid-19, in which the virus hit mainly sick elderly, but response impacted working-age adults and children heavily and will continue to have effect, due to increased poverty and debt; reduced education and child marriage, in future generations.

    These have disproportionately affected lower-income people, and particularly women. The lack of recognition of this in this document, though they are recognized by the World Bank and UN agencies elsewhere, must raise real questions on whether this Agreement has been thoroughly thought through, and the process of development been sufficiently inclusive and objective.

    Chapter I. Introduction

    Article 1. Use of terms

    (i) “pathogen with pandemic potential” means any pathogen that has been identified to infect a human and that is: novel (not yet characterized) or known (including a variant of a known pathogen), potentially highly transmissible and/or highly virulent with the potential to cause a public health emergency of international concern.

    This provides a very wide scope to alter provisions. Any pathogen that can infect humans and is potentially highly transmissible or virulent, though yet uncharacterized means virtually any coronavirus, influenza virus, or a plethora of other relatively common pathogen groups. The IHR Amendments intend that the DG alone can make this call, over the advice of others, as occurred with monkeypox in 2022.

    (j) “persons in vulnerable situations” means individuals, groups or communities with a disproportionate increased risk of infection, severity, disease or mortality.

    This is a good definition – in Covid-19 context, would mean the sick elderly, and so is relevant to targeting a response.

    “Universal health coverage” means that all people have access to the full range of quality health services they need, when and where they need them, without financial hardship.

    While the general UHC concept is good, it is time a sensible (rather than patently silly) definition was adopted. Society cannot afford the full range of possible interventions and remedies for all, and clearly there is a scale of cost vs benefit that prioritizes certain ones over others. Sensible definitions make action more likely, and inaction harder to justify. One could argue that none should have the full range until all have good basic care, but clearly the earth will not support ‘the full range’ for 8 billion people.

    Article 2. Objective

    This Agreement is specifically for pandemics (a poorly defined term but essentially a pathogen that spreads rapidly across national borders). In contrast, the IHR amendments accompanying it are broader in scope – for any public health emergencies of international concern.

    Article 3. Principles

    2. the sovereign right of States to adopt, legislate and implement legislation

    The amendments to the IHR require States to undertake to follow WHO instructions ahead of time, before such instruction and context are known. These two documents must be understood, as noted later in the Agreement draft, as complementary.

    3. equity as the goal and outcome of pandemic prevention, preparedness and response, ensuring the absence of unfair, avoidable or remediable differences among groups of people.

    This definition of equity here needs clarification. In the pandemic context, the WHO emphasized commodity (vaccine) equity during the Covid-19 response. Elimination of differences implied equal access to Covid-19 vaccines in countries with large aging, obese highly vulnerable populations (e.g. the USA or Italy), and those with young populations at minimal risk and with far more pressing health priorities (e.g. Niger or Uganda).

    Alternatively, but equally damaging, equal access to different age groups within a country when the risk-benefit ratio is clearly greatly different. This promotes worse health outcomes by diverting resources from where they are most useful, as it ignores heterogeneity of risk. Again, an adult approach is required in international agreements, rather than feel-good sentences, if they are going to have a positive impact.

    5. …a more equitable and better prepared world to prevent, respond to and recover from pandemics

    As with ‘3’ above, this raises a fundamental problem: What if health equity demands that some populations divert resources to childhood nutrition and endemic diseases rather than the latest pandemic, as these are likely of far higher burden to many younger but lower-income populations? This would not be equity in the definition implied here, but would clearly lead to better and more equal health outcomes.

    The WHO must decide whether it is about uniform action, or minimizing poor health, as these are clearly very different. They are the difference between the WHO’s commodity equity, and true health equity.

    Chapter II. The world together equitably: achieving equity in, for and through pandemic prevention, preparedness and response

    Equity in health should imply a reasonably equal chance of overcoming or avoiding preventable sickness. The vast majority of sickness and death is due to either non-communicable diseases often related to lifestyle, such as obesity and type 2 diabetes mellitus, undernutrition in childhood, and endemic infectious diseases such as tuberculosis, malaria, and HIV/AIDS. Achieving health equity would primarily mean addressing these.

    In this chapter of the draft Pandemic Agreement, equity is used to imply equal access to specific health commodities, particularly vaccines, for intermittent health emergencies, although these exert a small fraction of the burden of other diseases. It is, specifically, commodity-equity, and not geared to equalizing overall health burden but to enabling centrally-coordinated homogenous responses to unusual events.

    Article 4. Pandemic prevention and surveillance

    2. The Parties shall undertake to cooperate:

    (b) in support of…initiatives aimed at preventing pandemics, in particular those that improve surveillance, early warning and risk assessment; .…and identify settings and activities presenting a risk of emergence and re-emergence of pathogens with pandemic potential.

    (c-h) [Paragraphs on water and sanitation, infection control, strengthening of biosafety, surveillance and prevention of vector-born diseases, and addressing antimicrobial resistance.]

    The WHO intends the Agreement to have force under international law. Therefore, countries are undertaking to put themselves under force of international law in regards to complying with the agreement’s stipulations.

    The provisions under this long article mostly cover general health stuff that countries try to do anyway. The difference will be that countries will be assessed on progress. Assessment can be fine if in context, less fine if it consists of entitled ‘experts’ from wealthy countries with little local knowledge or context. Perhaps such compliance is best left to national authorities, who are more in use with local needs and priorities. The justification for the international bureaucracy being built to support this, while fun for those involved, is unclear and will divert resources from actual health work.

    6. The Conference of the Parties may adopt, as necessary, guidelines, recommendations and standards, including in relation to pandemic prevention capacities, to support the implementation of this Article.

    Here and later, the COP is invoked as a vehicle to decide on what will actually be done. The rules are explained later (Articles 21-23). While allowing more time is sensible, it begs the question of why it is not better to wait and discuss what is needed in the current INB process, before committing to a legally-binding agreement. This current article says nothing not already covered by the IHR2005 or other ongoing programs.

    Article 5. One Health approach to pandemic prevention, preparedness and response

    Nothing specific or new in this article. It seems redundant (it is advocating a holistic approach mentioned elsewhere) and so presumably is just to get the term ‘One Health’ into the agreement. (One could ask, why bother?)

    Some mainstream definitions of One Health (e.g. Lancet) consider that it means non-human species are on a par with humans in terms of rights and importance. If this is meant here, clearly most Member States would disagree. So we may assume that it is just words to keep someone happy (a little childish in an international document, but the term ‘One Health’ has been trending, like ‘equity,’ as if the concept of holistic approaches to public health were new).

    Article 6. Preparedness, health system resilience and recovery

    2. Each Party commits…[to] :

    (a) routine and essential health services during pandemics with a focus on primary health care, routine immunization and mental health care, and with particular attention to persons in vulnerable situations

    (b) developing, strengthening and maintaining health infrastructure

    (c) developing post-pandemic health system recovery strategies

    (d) developing, strengthening and maintaining: health information systems

    This is good, and (a) seems to require avoidance of lockdowns (which inevitably cause the harms listed). Unfortunately other WHO documents lead one to assume this is not the intent…It does appear therefore that this is simply another list of fairly non-specific feel-good measures that have no useful place in a new legally-binding agreement, and which most countries are already undertaking.

    (e) promoting the use of social and behavioural sciences, risk communication and community engagement for pandemic prevention, preparedness and response.

    This requires clarification, as the use of behavioral science during the Covid-19 response involved deliberate inducement of fear to promote behaviors that people would not otherwise follow (e.g. Spi-B). It is essential here that the document clarifies how behavioral science should be used ethically in healthcare. Otherwise, this is also a quite meaningless provision.

    Article 7. Health and care workforce

    This long Article discusses health workforce, training, retention, non-discrimination, stigma, bias, adequate remuneration, and other standard provisions for workplaces. It is unclear why it is included in a legally binding pandemic agreement, except for:

    4. [The Parties]…shall invest in establishing, sustaining, coordinating and mobilizing a skilled and trained multidisciplinary global public health emergency workforce…Parties having established emergency health teams should inform WHO thereof and make best efforts to respond to requests for deployment…

    Emergency health teams established (within capacity etc.) – are something countries already do, when they have capacity. There is no reason to have this as a legally-binding instrument, and clearly no urgency to do so.

    Article 8. Preparedness monitoring and functional reviews

    1. The Parties shall, building on existing and relevant tools, develop and implement an inclusive, transparent, effective and efficient pandemic prevention, preparedness and response monitoring and evaluation system.

    2. Each Party shall assess, every five years, with technical support from the WHO Secretariat upon request, the functioning and readiness of, and gaps in, its pandemic prevention, preparedness and response capacity, based on the relevant tools and guidelines developed by WHO in partnership with relevant organizations at international, regional and sub-regional levels.

    Note that this is being required of countries that are already struggling to implement monitoring systems for major endemic diseases, including tuberculosis, malaria, HIV, and nutritional deficiencies. They will be legally bound to divert resources to pandemic prevention. While there is some overlap, it will inevitably divert resources from currently underfunded programs for diseases of far higher local burdens, and so (not theoretically, but inevitably) raise mortality. Poor countries are being required to put resources into problems deemed significant by richer countries.

    Article 9. Research and development

    Various general provisions about undertaking background research that countries are generally doing anyway, but with an ’emerging disease’ slant. Again, the INB fails to justify why this diversion of resources from researching greater disease burdens should occur in all countries (why not just those with excess resources?).

    Article 10. Sustainable and geographically diversified production

    Mostly non-binding but suggested cooperation on making pandemic-related products available, including support for manufacturing in “inter-pandemic times” (a fascinating rendering of ‘normal’), when they would only be viable through subsidies. Much of this is probably unimplementable, as it would not be practical to maintain facilities in most or all countries on stand-by for rare events, at cost of resources otherwise useful for other priorities. The desire to increase production in ‘developing’ countries will face major barriers and costs in terms of maintaining quality of production, particularly as many products will have limited use outside of rare outbreak situations.

    Article 11. Transfer of technology and know-how

    This article, always problematic for large pharmaceutical corporations sponsoring much WHO outbreak activities, is now watered down to weak requirements to ‘consider,’ promote,’ provide, within capabilities’ etc.

    Article 12. Access and benefit sharing

    This Article is intended to establish the WHO Pathogen Access and Benefit-Sharing System (PABS System). PABS is intended to “ensure rapid, systematic and timely access to biological materials of pathogens with pandemic potential and the genetic sequence data.” This system is of potential high relevance and needs to be interpreted in the context that SARS-CoV-2, the pathogen causing the recent Covid-19 outbreak, was highly likely to have escaped from a laboratory. PABS is intended to expand the laboratory storage, transport, and handling of such viruses, under the oversight of the WHO, an organization outside of national jurisdiction with no significant direct experience in handling biological materials.

    3. When a Party has access to a pathogen [it shall]:

    (a) share with WHO any pathogen sequence information as soon as it is available to the Party;

    (b) as soon as biological materials are available to the Party, provide the materials to one or more laboratories and/or biorepositories participating in WHO-coordinated laboratory networks (CLNs),

    Subsequent clauses state that benefits will be shared, and seek to prevent recipient laboratories from patenting materials received from other countries. This has been a major concern of low-and middle-income countries previously, who perceive that institutions in wealthy countries patent and benefit from materials derived from less-wealthy populations. It remains to be seen whether provisions here will be sufficient to address this.

    The article then becomes yet more concerning:

    6. WHO shall conclude legally binding standard PABS contracts with manufacturers to provide the following, taking into account the size, nature and capacities of the manufacturer:

    (a) annual monetary contributions to support the PABS System and relevant capacities in countries; the determination of the annual amount, use, and approach for monitoring and accountability, shall be finalized by the Parties;

    (b) real-time contributions of relevant diagnostics, therapeutics or vaccines produced by the manufacturer, 10% free of charge and 10% at not-for-profit prices during public health emergencies of international concern or pandemics, …

    It is clearly intended that the WHO becomes directly involved in setting up legally binding manufacturing contracts, despite the WHO being outside of national jurisdictional oversight, within the territories of Member States. The PABS system, and therefore its staff and dependent entities, are also to be supported in part by funds from the manufacturers whom they are supposed to be managing. The income of the organization will be dependent on maintaining positive relationships with these private entities in a similar way in which many national regulatory agencies are dependent upon funds from pharmaceutical companies whom their staff ostensibly regulate. In this case, the regulator will be even further removed from public oversight.

    The clause on 10% (why 10?) products being free of charge, and similar at cost, while ensuring lower-priced commodities irrespective of actual need (the outbreak may be confined to wealthy countries). The same entity, the WHO, will determine whether the triggering emergency exists, determine the response, and manage the contracts to provide the commodities, without direct jurisdictional oversight regarding the potential for corruption or conflict of interest. It is a remarkable system to suggest, irrespective of political or regulatory environment.

    8. The Parties shall cooperate…public financing of research and development, prepurchase agreements, or regulatory procedures, to encourage and facilitate as many manufacturers as possible to enter into standard PABS contracts as early as possible.

    The article envisions that public funding will be used to build the process, ensuring essentially no-risk private profit.

    10. To support operationalization of the PABS System, WHO shall…make such contracts public, while respecting commercial confidentiality.

    The public may know whom contracts are made with, but not all details of the contracts. There will therefore be no independent oversight of the clauses agreed between the WHO, a body outside of national jurisdiction and dependent of commercial companies for funding some of its work and salaries, and these same companies, on ‘needs’ that the WHO itself will have sole authority, under the proposed amendments to the IHR, to determine.

    The Article further states that the WHO shall use its own product regulatory system (prequalification) and Emergency Use Listing Procedure to open and stimulate markets for the manufacturers of these products.

    It is doubtful that any national government could make such an overall agreement, yet in May 2024 they will be voting to provide this to what is essentially a foreign, and partly privately financed, entity.

    Article 13. Supply chain and logistics

    The WHO will become convenor of a ‘Global Supply Chain and Logistics Network’ for commercially-produced products, to be supplied under WHO contracts when and where the WHO determines, whilst also having the role of ensuring safety of such products.

    Having mutual support coordinated between countries is good. Having this run by an organization that is significantly funded directly by those gaining from the sale of these same commodities seems reckless and counterintuitive. Few countries would allow this (or at least plan for it).

    For this to occur safely, the WHO would logically have to forgo all private investment, and greatly restrict national specified funding contributions. Otherwise, the conflicts of interest involved would destroy confidence in the system. There is no suggestion of such divestment from the WHO, but rather, as in Article 12, private sector dependency, directly tied to contracts, will increase.

    Article 13bis: National procurement- and distribution-related provisions

    While suffering the same (perhaps unavoidable) issues regarding commercial confidentiality, this alternate Article 13 seems far more appropriate, keeping commercial issues under national jurisdiction and avoiding the obvious conflict of interests that underpin funding for WHO activities and staffing.

    Article 14. Regulatory systems strengthening

    This entire Article reflects initiatives and programs already in place. Nothing here appears likely to add to current effort.

    Article 15. Liability and compensation management

    1. Each Party shall consider developing, as necessary and in accordance with applicable law, national strategies for managing liability in its territory related to pandemic vaccines…no-fault compensation mechanisms…

    2. The Parties…shall develop recommendations for the establishment and implementation of national, regional and/or global no-fault compensation mechanisms and strategies for managing liability during pandemic emergencies, including with regard to individuals that are in a humanitarian setting or vulnerable situations.

    This is quite remarkable, but also reflects some national legislation, in removing any fault or liability specifically from vaccine manufacturers, for harms done in pushing out vaccines to the public. During the Covid-19 response, genetic therapeutics being developed by BioNtech and Moderna were reclassified as vaccines, on the basis that an immune response is stimulated after they have modified intracellular biochemical pathways as a medicine normally does.

    This enabled specific trials normally required for carcinogenicity and teratogenicity to be bypassed, despite raised fetal abnormality rates in animal trials. It will enable the CEPI 100-day vaccine program, supported with private funding to support private mRNA vaccine manufacturers, to proceed without any risk to the manufacturer should there be subsequent public harm.

    Together with an earlier provision on public funding of research and manufacturing readiness, and the removal of former wording requiring intellectual property sharing in Article 11, this ensures vaccine manufacturers and their investors make profit in effective absence of risk.

    These entities are currently heavily invested in support for WHO, and were strongly aligned with the introduction of newly restrictive outbreak responses that emphasized and sometimes mandated their products during the Covid-19 outbreak.

    Article 16. International collaboration and cooperation

    A somewhat pointless article. It suggests that countries cooperate with each other and the WHO to implement the other agreements in the Agreement.

    Article 17. Whole-of-government and whole-of-society approaches

    A list of essentially motherhood provisions related to planning for a pandemic. However, countries will legally be required to maintain a ‘national coordination multisectoral body’ for PPPR. This will essentially be an added burden on budgets, and inevitably divert further resources from other priorities. Perhaps just strengthening current infectious disease and nutritional programs would be more impactful. (Nowhere in this Agreement is nutrition discussed (essential for resilience to pathogens) and minimal wording is included on sanitation and clean water (other major reasons for reduction in infectious disease mortality over past centuries).

    However, the ‘community ownership’ wording is interesting (“empower and enable community ownership of, and contribution to, community readiness for and resilience [for PPPR]”), as this directly contradicts much of the rest of the Agreement, including the centralization of control under the Conference of Parties, requirements for countries to allocate resources to pandemic preparedness over other community priorities, and the idea of inspecting and assessing adherence to the centralized requirements of the Agreement. Either much of the rest of the Agreement is redundant, or this wording is purely for appearance and not to be followed (and therefore should be removed).

    Article 18. Communication and public awareness

    1. Each Party shall promote timely access to credible and evidence-based information …with the aim of countering and addressing misinformation or disinformation…

    2. The Parties shall, as appropriate, promote and/or conduct research and inform policies on factors that hinder or strengthen adherence to public health and social measures in a pandemic, as well as trust in science and public health institutions and agencies.

    The key word is as appropriate, given that many agencies, including the WHO, have overseen or aided policies during the Covid-19 response that have greatly increased poverty, child marriage, teenage pregnancy, and education loss.

    As the WHO has been shown to be significantly misrepresenting pandemic risk in the process of advocating for this Agreement and related instruments, its own communications would also fall outside the provision here related to evidence-based information, and fall within normal understandings of misinformation. It could not therefore be an arbiter of correctness of information here, so the Article is not implementable. Rewritten to recommend accurate evidence-based information being promoted, it would make good sense, but this is not an issue requiring a legally binding international agreement.

    Article 19. Implementation and support

    3. The WHO Secretariat…organize the technical and financial assistance necessary to address such gaps and needs in implementing the commitments agreed upon under the Pandemic Agreement and the International Health Regulations (2005).

    As the WHO is dependent on donor support, its ability to address gaps in funding within Member States is clearly not something it can guarantee. The purpose of this article is unclear, repeating in paragraphs 1 and 2 the earlier intent for countries to generally support each other.

    Article 20. Sustainable financing

    1. The Parties commit to working together…In this regard, each Party, within the means and resources at its disposal, shall:

    (a) prioritize and maintain or increase, as necessary, domestic funding for pandemic prevention, preparedness and response, without undermining other domestic public health priorities including for: (i) strengthening and sustaining capacities for the prevention, preparedness and response to health emergencies and pandemics, in particular the core capacities of the International Health Regulations (2005);…

    This is silly wording, as countries obviously have to prioritize within budgets, so that moving funds to one area means removing from another. The essence of public health policy is weighing and making such decisions; this reality seems to be ignored here through wishful thinking. (a) is clearly redundant, as the IHR (2005) already exists and countries have agreed to support it.

    3. A Coordinating Financial Mechanism (the “Mechanism”) is hereby established to support the implementation of both the WHO Pandemic Agreement and the International Health Regulations (2005)

    This will be in parallel to the Pandemic Fund recently commenced by the World Bank – an issue not lost on INB delegates and so likely to change here in the final version. It will also be additive to the Global Fund to fight AIDS, tuberculosis, and malaria, and other health financing mechanisms, and so require another parallel international bureaucracy, presumably based in Geneva.

    It is intended to have its own capacity to “conduct relevant analyses on needs and gaps, in addition to tracking cooperation efforts,” so it will not be a small undertaking.

    Chapter III. Institutional and final provisions

    Article 21. Conference of the Parties

    1. A Conference of the Parties is hereby established.

    2. The Conference of the Parties shall keep under regular review, every three years, the implementation of the WHO Pandemic Agreement and take the decisions necessary to promote its effective implementation.

    This sets up the governing body to oversee this Agreement (another body requiring a secretariat and support). It is intended to meet within a year of the Agreement coming into force, and then set its own rules on meeting thereafter. It is likely that many provisions outlined in this draft of the Agreement will be deferred to the COP for further discussion.

    Articles 22 – 37

    These articles cover the functioning of the Conference of Parties (COP) and various administrative issues.

    Of note, ‘block votes’ will be allowed from regional bodies (e.g. the EU).

    The WHO will provide the secretariat.

    Under Article 24 is noted:

    3. Nothing in the WHO Pandemic Agreement shall be interpreted as providing the Secretariat of the World Health Organization, including the WHO Director-General, any authority to direct, order, alter or otherwise prescribe the domestic laws or policies of any Party, or to mandate or otherwise impose any requirements that Parties take specific actions, such as ban or accept travellers, impose vaccination mandates or therapeutic or diagnostic measures, or implement lockdowns.

    These provisions are explicitly stated in the proposed amendments to the IHR, to be considered alongside this agreement. Article 26 notes that the IHR is to be interpreted as compatible, thereby confirming that the IHR provisions including border closures and limits on freedom of movement, mandated vaccination, and other lockdown measures are not negated by this statement.

    As Article 26 states: “The Parties recognize that the WHO Pandemic Agreement and the International Health Regulations should be interpreted so as to be compatible.”

    Some would consider this subterfuge – The Director-General recently labeled as liars those who claimed the Agreement included these powers, whilst failing to acknowledge the accompanying IHR amendments. The WHO could do better in avoiding misleading messaging, especially when this involves denigration of the public.

    Article 32 (Withdrawal) requires that, once adopted, Parties cannot withdraw for a total of 3 years (giving notice after a minimum of 2 years). Financial obligations undertaken under the agreement continue beyond that time.

    Finally, the Agreement will come into force, assuming a two-thirds majority in the WHA is achieved (Article 19, WHO Constitution), 30 days after the fortieth country has ratified it.

    Further reading:

    WHO Pandemic Agreement Intergovernmental Negotiating Board website:

    https://inb.who.int/

    International Health Regulations Working Group website:

    https://apps.who.int/gb/wgihr/index.html

    On background to the WHO texts:

    Amendments to WHO’s International Health Regulations: An Annotated Guide
    An Unofficial Q&A on International Health Regulations
    On urgency and burden of pandemics:

    https://essl.leeds.ac.uk/downloads/download/228/rational-policy-over-panic

    Disease X and Davos: This is Not the Way to Evaluate and Formulate Public Health Policy
    Before Preparing for Pandemics, We Need Better Evidence of Risk
    Revised Draft of the negotiating text of the WHO Pandemic Agreement:

    Published under a Creative Commons Attribution 4.0 International License
    For reprints, please set the canonical link back to the original Brownstone Institute Article and Author.

    Authors

    David Bell
    David Bell, Senior Scholar at Brownstone Institute, is a public health physician and biotech consultant in global health. He is a former medical officer and scientist at the World Health Organization (WHO), Programme Head for malaria and febrile diseases at the Foundation for Innovative New Diagnostics (FIND) in Geneva, Switzerland, and Director of Global Health Technologies at Intellectual Ventures Global Good Fund in Bellevue, WA, USA.

    View all posts
    Thi Thuy Van Dinh
    Dr. Thi Thuy Van Dinh (LLM, PhD) worked on international law in the United Nations Office on Drugs and Crime and the Office of the High Commissioner for Human Rights. Subsequently, she managed multilateral organization partnerships for Intellectual Ventures Global Good Fund and led environmental health technology development efforts for low-resource settings.

    View all posts
    Your financial backing of Brownstone Institute goes to support writers, lawyers, scientists, economists, and other people of courage who have been professionally purged and displaced during the upheaval of our times. You can help get the truth out through their ongoing work.

    https://brownstone.org/articles/the-who-pandemic-agreement-a-guide/

    https://www.minds.com/donshafi911/blog/the-who-pandemic-agreement-a-guide-1621719398509187077
    The WHO Pandemic Agreement: A Guide By David Bell, Thi Thuy Van Dinh March 22, 2024 Government, Society 30 minute read The World Health Organization (WHO) and its 194 Member States have been engaged for over two years in the development of two ‘instruments’ or agreements with the intent of radically changing the way pandemics and other health emergencies are managed. One, consisting of draft amendments to the existing International health Regulations (IHR), seeks to change the current IHR non-binding recommendations into requirements or binding recommendations, by having countries “undertake” to implement those given by the WHO in future declared health emergencies. It covers all ‘public health emergencies of international concern’ (PHEIC), with a single person, the WHO Director-General (DG) determining what a PHEIC is, where it extends, and when it ends. It specifies mandated vaccines, border closures, and other directives understood as lockdowns among the requirements the DG can impose. It is discussed further elsewhere and still under negotiation in Geneva. A second document, previously known as the (draft) Pandemic Treaty, then Pandemic Accord, and more recently the Pandemic Agreement, seeks to specify governance, supply chains, and various other interventions aimed at preventing, preparing for, and responding to, pandemics (pandemic prevention, preparedness and response – PPPR). It is currently being negotiated by the Intergovernmental Negotiating Body (INB). Both texts will be subject to a vote at the May 2024 World Health Assembly (WHA) in Geneva, Switzerland. These votes are intended, by those promoting these projects, to bring governance of future multi-country healthcare emergencies (or threats thereof) under the WHO umbrella. The latest version of the draft Pandemic Agreement (here forth the ‘Agreement’) was released on 7th March 2024. However, it is still being negotiated by various committees comprising representatives of Member States and other interested entities. It has been through multiple iterations over two years, and looks like it. With the teeth of the pandemic response proposals in the IHR, the Agreement looks increasingly irrelevant, or at least unsure of its purpose, picking up bits and pieces in a half-hearted way that the IHR amendments do not, or cannot, include. However, as discussed below, it is far from irrelevant. Historical Perspective These aim to increase the centralization of decision-making within the WHO as the “directing and coordinating authority.” This terminology comes from the WHO’s 1946 Constitution, developed in the aftermath of the Second World War as the world faced the outcomes of European fascism and the similar approaches widely imposed through colonialist regimes. The WHO would support emerging countries, with rapidly expanding and poorly resourced populations struggling under high disease burdens, and coordinate some areas of international support as these sovereign countries requested it. The emphasis of action was on coordinating rather than directing. In the 80 years prior to the WHO’s existence, international public health had grown within a more directive mindset, with a series of meetings by colonial and slave-owning powers from 1851 to manage pandemics, culminating in the inauguration of the Office Internationale d’Hygiene Publique in Paris in 1907, and later the League of Nations Health Office. World powers imposed health dictates on those less powerful, in other parts of the world and increasingly on their own population through the eugenics movement and similar approaches. Public health would direct, for the greater good, as a tool of those who wish to direct the lives of others. The WHO, governed by the WHA, was to be very different. Newly independent States and their former colonial masters were ostensibly on an equal footing within the WHA (one country – one vote), and the WHO’s work overall was to be an example of how human rights could dominate the way society works. The model for international public health, as exemplified in the Declaration of Alma Ata in 1978, was to be horizontal rather than vertical, with communities and countries in the driving seat. With the evolution of the WHO in recent decades from a core funding model (countries give money, the WHO decides under the WHA guidance how to spend it) to a model based on specified funding (funders, both public and increasingly private, instruct the WHO on how to spend it), the WHO has inevitably changed to become a public-private partnership required to serve the interests of funders rather than populations. As most funding comes from a few countries with major Pharma industrial bases, or private investors and corporations in the same industry, the WHO has been required to emphasize the use of pharmaceuticals and downplay evidence and knowledge where these clash (if it wants to keep all its staff funded). It is helpful to view the draft Agreement, and the IHR amendments, in this context. Why May 2024? The WHO, together with the World Bank, G20, and other institutions have been emphasizing the urgency of putting the new pandemic instruments in place earnestly, before the ‘next pandemic.’ This is based on claims that the world was unprepared for Covid-19, and that the economic and health harm would be somehow avoidable if we had these agreements in place. They emphasize, contrary to evidence that Covid-19 virus (SARS-CoV-2) origins involve laboratory manipulation, that the main threats we face are natural, and that these are increasing exponentially and present an “existential” threat to humanity. The data on which the WHO, the World Bank, and G20 base these claims demonstrates the contrary, with reported natural outbreaks having increased as detection technologies have developed, but reducing in mortality rate, and in numbers, over the past 10 to 20 years.. A paper cited by the World Bank to justify urgency and quoted as suggesting a 3x increase in risk in the coming decade actually suggests that a Covid-19-like event would occur roughly every 129 years, and a Spanish-flu repetition every 292 to 877 years. Such predictions are unable to take into account the rapidly changing nature of medicine and improved sanitation and nutrition (most deaths from Spanish flu would not have occurred if modern antibiotics had been available), and so may still overestimate risk. Similarly, the WHO’s own priority disease list for new outbreaks only includes two diseases of proven natural origin that have over 1,000 historical deaths attributed to them. It is well demonstrated that the risk and expected burden of pandemics is misrepresented by major international agencies in current discussions. The urgency for May 2024 is clearly therefore inadequately supported, firstly because neither the WHO nor others have demonstrated how the harms accrued through Covid-19 would be reduced through the measures proposed, and secondly because the burden and risk is misrepresented. In this context, the state of the Agreement is clearly not where it should be as a draft international legally binding agreement intended to impose considerable financial and other obligations on States and populations. This is particularly problematic as the proposed expenditure; the proposed budget is over $31 billion per year, with over $10 billion more on other One Health activities. Much of this will have to be diverted from addressing other diseases burdens that impose far greater burden. This trade-off, essential to understand in public health policy development, has not yet been clearly addressed by the WHO. The WHO DG stated recently that the WHO does not want the power to impose vaccine mandates or lockdowns on anyone, and does not want this. This begs the question of why either of the current WHO pandemic instruments is being proposed, both as legally binding documents. The current IHR (2005) already sets out such approaches as recommendations the DG can make, and there is nothing non-mandatory that countries cannot do now without pushing new treaty-like mechanisms through a vote in Geneva. Based on the DG’s claims, they are essentially redundant, and what new non-mandatory clauses they contain, as set out below, are certainly not urgent. Clauses that are mandatory (Member States “shall”) must be considered within national decision-making contexts and appear against the WHO’s stated intent. Common sense would suggest that the Agreement, and the accompanying IHR amendments, be properly thought through before Member States commit. The WHO has already abandoned the legal requirement for a 4-month review time for the IHR amendments (Article 55.2 IHR), which are also still under negotiation just 2 months before the WHA deadline. The Agreement should also have at least such a period for States to properly consider whether to agree – treaties normally take many years to develop and negotiate and no valid arguments have been put forward as to why these should be different. The Covid-19 response resulted in an unprecedented transfer of wealth from those of lower income to the very wealthy few, completely contrary to the way in which the WHO was intended to affect human society. A considerable portion of these pandemic profits went to current sponsors of the WHO, and these same corporate entities and investors are set to further benefit from the new pandemic agreements. As written, the Pandemic Agreement risks entrenching such centralization and profit-taking, and the accompanying unprecedented restrictions on human rights and freedoms, as a public health norm. To continue with a clearly flawed agreement simply because of a previously set deadline, when no clear population benefit is articulated and no true urgency demonstrated, would therefore be a major step backward in international public health. Basic principles of proportionality, human agency, and community empowerment, essential for health and human rights outcomes, are missing or paid lip-service. The WHO clearly wishes to increase its funding and show it is ‘doing something,’ but must first articulate why the voluntary provisions of the current IHR are insufficient. It is hoped that by systematically reviewing some key clauses of the agreement here, it will become clear why a rethink of the whole approach is necessary. The full text is found below. The commentary below concentrates on selected draft provisions of the latest publicly available version of the draft agreement that seem to be unclear or potentially problematic. Much of the remaining text is essentially pointless as it reiterates vague intentions to be found in other documents or activities which countries normally undertake in the course of running health services, and have no place in a focused legally-binding international agreement. REVISED Draft of the negotiating text of the WHO Pandemic Agreement. 7th March, 2024 Preamble Recognizing that the World Health Organization…is the directing and coordinating authority on international health work. This is inconsistent with a recent statement by the WHO DG that the WHO has no interest or intent to direct country health responses. To reiterate it here suggests that the DG is not representing the true position regarding the Agreement. “Directing authority” is however in line with the proposed IHR Amendments (and the WHO’s Constitution), under which countries will “undertake” ahead of time to follow the DG’s recommendations (which thereby become instructions). As the HR amendments make clear, this is intended to apply even to a perceived threat rather than actual harm. Recalling the constitution of the World Health Organization…highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition. This statement recalls fundamental understandings of public health, and is of importance here as it raises the question of why the WHO did not strongly condemn prolonged school closures, workplace closures, and other impoverishing policies during the Covid-19 response. In 2019, WHO made clear that these dangers should prevent actions we now call ‘lockdowns’ from being imposed. Deeply concerned by the gross inequities at national and international levels that hindered timely and equitable access to medical and other Covid-19 pandemic-related products, and the serious shortcomings in pandemic preparedness. In terms of health equity (as distinct from commodity of ‘vaccine’ equity), inequity in the Covid-19 response was not in failing to provide a vaccine against former variants to immune, young people in low-income countries who were at far higher risk from endemic diseases, but in the disproportionate harm to them of uniformly-imposed NPIs that reduced current and future income and basic healthcare, as was noted by the WHO in 2019 Pandemic Influenza recommendations. The failure of the text to recognize this suggests that lessons from Covid-19 have not informed this draft Agreement. The WHO has not yet demonstrated how pandemic ‘preparedness,’ in the terms they use below, would have reduced impact, given that there is poor correlation between strictness or speed of response and eventual outcomes. Reiterating the need to work towards…an equitable approach to mitigate the risk that pandemics exacerbate existing inequities in access to health services, As above – in the past century, the issue of inequity has been most pronounced in pandemic response, rather than the impact of the virus itself (excluding the physiological variation in risk). Most recorded deaths from acute pandemics, since the Spanish flu, were during Covid-19, in which the virus hit mainly sick elderly, but response impacted working-age adults and children heavily and will continue to have effect, due to increased poverty and debt; reduced education and child marriage, in future generations. These have disproportionately affected lower-income people, and particularly women. The lack of recognition of this in this document, though they are recognized by the World Bank and UN agencies elsewhere, must raise real questions on whether this Agreement has been thoroughly thought through, and the process of development been sufficiently inclusive and objective. Chapter I. Introduction Article 1. Use of terms (i) “pathogen with pandemic potential” means any pathogen that has been identified to infect a human and that is: novel (not yet characterized) or known (including a variant of a known pathogen), potentially highly transmissible and/or highly virulent with the potential to cause a public health emergency of international concern. This provides a very wide scope to alter provisions. Any pathogen that can infect humans and is potentially highly transmissible or virulent, though yet uncharacterized means virtually any coronavirus, influenza virus, or a plethora of other relatively common pathogen groups. The IHR Amendments intend that the DG alone can make this call, over the advice of others, as occurred with monkeypox in 2022. (j) “persons in vulnerable situations” means individuals, groups or communities with a disproportionate increased risk of infection, severity, disease or mortality. This is a good definition – in Covid-19 context, would mean the sick elderly, and so is relevant to targeting a response. “Universal health coverage” means that all people have access to the full range of quality health services they need, when and where they need them, without financial hardship. While the general UHC concept is good, it is time a sensible (rather than patently silly) definition was adopted. Society cannot afford the full range of possible interventions and remedies for all, and clearly there is a scale of cost vs benefit that prioritizes certain ones over others. Sensible definitions make action more likely, and inaction harder to justify. One could argue that none should have the full range until all have good basic care, but clearly the earth will not support ‘the full range’ for 8 billion people. Article 2. Objective This Agreement is specifically for pandemics (a poorly defined term but essentially a pathogen that spreads rapidly across national borders). In contrast, the IHR amendments accompanying it are broader in scope – for any public health emergencies of international concern. Article 3. Principles 2. the sovereign right of States to adopt, legislate and implement legislation The amendments to the IHR require States to undertake to follow WHO instructions ahead of time, before such instruction and context are known. These two documents must be understood, as noted later in the Agreement draft, as complementary. 3. equity as the goal and outcome of pandemic prevention, preparedness and response, ensuring the absence of unfair, avoidable or remediable differences among groups of people. This definition of equity here needs clarification. In the pandemic context, the WHO emphasized commodity (vaccine) equity during the Covid-19 response. Elimination of differences implied equal access to Covid-19 vaccines in countries with large aging, obese highly vulnerable populations (e.g. the USA or Italy), and those with young populations at minimal risk and with far more pressing health priorities (e.g. Niger or Uganda). Alternatively, but equally damaging, equal access to different age groups within a country when the risk-benefit ratio is clearly greatly different. This promotes worse health outcomes by diverting resources from where they are most useful, as it ignores heterogeneity of risk. Again, an adult approach is required in international agreements, rather than feel-good sentences, if they are going to have a positive impact. 5. …a more equitable and better prepared world to prevent, respond to and recover from pandemics As with ‘3’ above, this raises a fundamental problem: What if health equity demands that some populations divert resources to childhood nutrition and endemic diseases rather than the latest pandemic, as these are likely of far higher burden to many younger but lower-income populations? This would not be equity in the definition implied here, but would clearly lead to better and more equal health outcomes. The WHO must decide whether it is about uniform action, or minimizing poor health, as these are clearly very different. They are the difference between the WHO’s commodity equity, and true health equity. Chapter II. The world together equitably: achieving equity in, for and through pandemic prevention, preparedness and response Equity in health should imply a reasonably equal chance of overcoming or avoiding preventable sickness. The vast majority of sickness and death is due to either non-communicable diseases often related to lifestyle, such as obesity and type 2 diabetes mellitus, undernutrition in childhood, and endemic infectious diseases such as tuberculosis, malaria, and HIV/AIDS. Achieving health equity would primarily mean addressing these. In this chapter of the draft Pandemic Agreement, equity is used to imply equal access to specific health commodities, particularly vaccines, for intermittent health emergencies, although these exert a small fraction of the burden of other diseases. It is, specifically, commodity-equity, and not geared to equalizing overall health burden but to enabling centrally-coordinated homogenous responses to unusual events. Article 4. Pandemic prevention and surveillance 2. The Parties shall undertake to cooperate: (b) in support of…initiatives aimed at preventing pandemics, in particular those that improve surveillance, early warning and risk assessment; .…and identify settings and activities presenting a risk of emergence and re-emergence of pathogens with pandemic potential. (c-h) [Paragraphs on water and sanitation, infection control, strengthening of biosafety, surveillance and prevention of vector-born diseases, and addressing antimicrobial resistance.] The WHO intends the Agreement to have force under international law. Therefore, countries are undertaking to put themselves under force of international law in regards to complying with the agreement’s stipulations. The provisions under this long article mostly cover general health stuff that countries try to do anyway. The difference will be that countries will be assessed on progress. Assessment can be fine if in context, less fine if it consists of entitled ‘experts’ from wealthy countries with little local knowledge or context. Perhaps such compliance is best left to national authorities, who are more in use with local needs and priorities. The justification for the international bureaucracy being built to support this, while fun for those involved, is unclear and will divert resources from actual health work. 6. The Conference of the Parties may adopt, as necessary, guidelines, recommendations and standards, including in relation to pandemic prevention capacities, to support the implementation of this Article. Here and later, the COP is invoked as a vehicle to decide on what will actually be done. The rules are explained later (Articles 21-23). While allowing more time is sensible, it begs the question of why it is not better to wait and discuss what is needed in the current INB process, before committing to a legally-binding agreement. This current article says nothing not already covered by the IHR2005 or other ongoing programs. Article 5. One Health approach to pandemic prevention, preparedness and response Nothing specific or new in this article. It seems redundant (it is advocating a holistic approach mentioned elsewhere) and so presumably is just to get the term ‘One Health’ into the agreement. (One could ask, why bother?) Some mainstream definitions of One Health (e.g. Lancet) consider that it means non-human species are on a par with humans in terms of rights and importance. If this is meant here, clearly most Member States would disagree. So we may assume that it is just words to keep someone happy (a little childish in an international document, but the term ‘One Health’ has been trending, like ‘equity,’ as if the concept of holistic approaches to public health were new). Article 6. Preparedness, health system resilience and recovery 2. Each Party commits…[to] : (a) routine and essential health services during pandemics with a focus on primary health care, routine immunization and mental health care, and with particular attention to persons in vulnerable situations (b) developing, strengthening and maintaining health infrastructure (c) developing post-pandemic health system recovery strategies (d) developing, strengthening and maintaining: health information systems This is good, and (a) seems to require avoidance of lockdowns (which inevitably cause the harms listed). Unfortunately other WHO documents lead one to assume this is not the intent…It does appear therefore that this is simply another list of fairly non-specific feel-good measures that have no useful place in a new legally-binding agreement, and which most countries are already undertaking. (e) promoting the use of social and behavioural sciences, risk communication and community engagement for pandemic prevention, preparedness and response. This requires clarification, as the use of behavioral science during the Covid-19 response involved deliberate inducement of fear to promote behaviors that people would not otherwise follow (e.g. Spi-B). It is essential here that the document clarifies how behavioral science should be used ethically in healthcare. Otherwise, this is also a quite meaningless provision. Article 7. Health and care workforce This long Article discusses health workforce, training, retention, non-discrimination, stigma, bias, adequate remuneration, and other standard provisions for workplaces. It is unclear why it is included in a legally binding pandemic agreement, except for: 4. [The Parties]…shall invest in establishing, sustaining, coordinating and mobilizing a skilled and trained multidisciplinary global public health emergency workforce…Parties having established emergency health teams should inform WHO thereof and make best efforts to respond to requests for deployment… Emergency health teams established (within capacity etc.) – are something countries already do, when they have capacity. There is no reason to have this as a legally-binding instrument, and clearly no urgency to do so. Article 8. Preparedness monitoring and functional reviews 1. The Parties shall, building on existing and relevant tools, develop and implement an inclusive, transparent, effective and efficient pandemic prevention, preparedness and response monitoring and evaluation system. 2. Each Party shall assess, every five years, with technical support from the WHO Secretariat upon request, the functioning and readiness of, and gaps in, its pandemic prevention, preparedness and response capacity, based on the relevant tools and guidelines developed by WHO in partnership with relevant organizations at international, regional and sub-regional levels. Note that this is being required of countries that are already struggling to implement monitoring systems for major endemic diseases, including tuberculosis, malaria, HIV, and nutritional deficiencies. They will be legally bound to divert resources to pandemic prevention. While there is some overlap, it will inevitably divert resources from currently underfunded programs for diseases of far higher local burdens, and so (not theoretically, but inevitably) raise mortality. Poor countries are being required to put resources into problems deemed significant by richer countries. Article 9. Research and development Various general provisions about undertaking background research that countries are generally doing anyway, but with an ’emerging disease’ slant. Again, the INB fails to justify why this diversion of resources from researching greater disease burdens should occur in all countries (why not just those with excess resources?). Article 10. Sustainable and geographically diversified production Mostly non-binding but suggested cooperation on making pandemic-related products available, including support for manufacturing in “inter-pandemic times” (a fascinating rendering of ‘normal’), when they would only be viable through subsidies. Much of this is probably unimplementable, as it would not be practical to maintain facilities in most or all countries on stand-by for rare events, at cost of resources otherwise useful for other priorities. The desire to increase production in ‘developing’ countries will face major barriers and costs in terms of maintaining quality of production, particularly as many products will have limited use outside of rare outbreak situations. Article 11. Transfer of technology and know-how This article, always problematic for large pharmaceutical corporations sponsoring much WHO outbreak activities, is now watered down to weak requirements to ‘consider,’ promote,’ provide, within capabilities’ etc. Article 12. Access and benefit sharing This Article is intended to establish the WHO Pathogen Access and Benefit-Sharing System (PABS System). PABS is intended to “ensure rapid, systematic and timely access to biological materials of pathogens with pandemic potential and the genetic sequence data.” This system is of potential high relevance and needs to be interpreted in the context that SARS-CoV-2, the pathogen causing the recent Covid-19 outbreak, was highly likely to have escaped from a laboratory. PABS is intended to expand the laboratory storage, transport, and handling of such viruses, under the oversight of the WHO, an organization outside of national jurisdiction with no significant direct experience in handling biological materials. 3. When a Party has access to a pathogen [it shall]: (a) share with WHO any pathogen sequence information as soon as it is available to the Party; (b) as soon as biological materials are available to the Party, provide the materials to one or more laboratories and/or biorepositories participating in WHO-coordinated laboratory networks (CLNs), Subsequent clauses state that benefits will be shared, and seek to prevent recipient laboratories from patenting materials received from other countries. This has been a major concern of low-and middle-income countries previously, who perceive that institutions in wealthy countries patent and benefit from materials derived from less-wealthy populations. It remains to be seen whether provisions here will be sufficient to address this. The article then becomes yet more concerning: 6. WHO shall conclude legally binding standard PABS contracts with manufacturers to provide the following, taking into account the size, nature and capacities of the manufacturer: (a) annual monetary contributions to support the PABS System and relevant capacities in countries; the determination of the annual amount, use, and approach for monitoring and accountability, shall be finalized by the Parties; (b) real-time contributions of relevant diagnostics, therapeutics or vaccines produced by the manufacturer, 10% free of charge and 10% at not-for-profit prices during public health emergencies of international concern or pandemics, … It is clearly intended that the WHO becomes directly involved in setting up legally binding manufacturing contracts, despite the WHO being outside of national jurisdictional oversight, within the territories of Member States. The PABS system, and therefore its staff and dependent entities, are also to be supported in part by funds from the manufacturers whom they are supposed to be managing. The income of the organization will be dependent on maintaining positive relationships with these private entities in a similar way in which many national regulatory agencies are dependent upon funds from pharmaceutical companies whom their staff ostensibly regulate. In this case, the regulator will be even further removed from public oversight. The clause on 10% (why 10?) products being free of charge, and similar at cost, while ensuring lower-priced commodities irrespective of actual need (the outbreak may be confined to wealthy countries). The same entity, the WHO, will determine whether the triggering emergency exists, determine the response, and manage the contracts to provide the commodities, without direct jurisdictional oversight regarding the potential for corruption or conflict of interest. It is a remarkable system to suggest, irrespective of political or regulatory environment. 8. The Parties shall cooperate…public financing of research and development, prepurchase agreements, or regulatory procedures, to encourage and facilitate as many manufacturers as possible to enter into standard PABS contracts as early as possible. The article envisions that public funding will be used to build the process, ensuring essentially no-risk private profit. 10. To support operationalization of the PABS System, WHO shall…make such contracts public, while respecting commercial confidentiality. The public may know whom contracts are made with, but not all details of the contracts. There will therefore be no independent oversight of the clauses agreed between the WHO, a body outside of national jurisdiction and dependent of commercial companies for funding some of its work and salaries, and these same companies, on ‘needs’ that the WHO itself will have sole authority, under the proposed amendments to the IHR, to determine. The Article further states that the WHO shall use its own product regulatory system (prequalification) and Emergency Use Listing Procedure to open and stimulate markets for the manufacturers of these products. It is doubtful that any national government could make such an overall agreement, yet in May 2024 they will be voting to provide this to what is essentially a foreign, and partly privately financed, entity. Article 13. Supply chain and logistics The WHO will become convenor of a ‘Global Supply Chain and Logistics Network’ for commercially-produced products, to be supplied under WHO contracts when and where the WHO determines, whilst also having the role of ensuring safety of such products. Having mutual support coordinated between countries is good. Having this run by an organization that is significantly funded directly by those gaining from the sale of these same commodities seems reckless and counterintuitive. Few countries would allow this (or at least plan for it). For this to occur safely, the WHO would logically have to forgo all private investment, and greatly restrict national specified funding contributions. Otherwise, the conflicts of interest involved would destroy confidence in the system. There is no suggestion of such divestment from the WHO, but rather, as in Article 12, private sector dependency, directly tied to contracts, will increase. Article 13bis: National procurement- and distribution-related provisions While suffering the same (perhaps unavoidable) issues regarding commercial confidentiality, this alternate Article 13 seems far more appropriate, keeping commercial issues under national jurisdiction and avoiding the obvious conflict of interests that underpin funding for WHO activities and staffing. Article 14. Regulatory systems strengthening This entire Article reflects initiatives and programs already in place. Nothing here appears likely to add to current effort. Article 15. Liability and compensation management 1. Each Party shall consider developing, as necessary and in accordance with applicable law, national strategies for managing liability in its territory related to pandemic vaccines…no-fault compensation mechanisms… 2. The Parties…shall develop recommendations for the establishment and implementation of national, regional and/or global no-fault compensation mechanisms and strategies for managing liability during pandemic emergencies, including with regard to individuals that are in a humanitarian setting or vulnerable situations. This is quite remarkable, but also reflects some national legislation, in removing any fault or liability specifically from vaccine manufacturers, for harms done in pushing out vaccines to the public. During the Covid-19 response, genetic therapeutics being developed by BioNtech and Moderna were reclassified as vaccines, on the basis that an immune response is stimulated after they have modified intracellular biochemical pathways as a medicine normally does. This enabled specific trials normally required for carcinogenicity and teratogenicity to be bypassed, despite raised fetal abnormality rates in animal trials. It will enable the CEPI 100-day vaccine program, supported with private funding to support private mRNA vaccine manufacturers, to proceed without any risk to the manufacturer should there be subsequent public harm. Together with an earlier provision on public funding of research and manufacturing readiness, and the removal of former wording requiring intellectual property sharing in Article 11, this ensures vaccine manufacturers and their investors make profit in effective absence of risk. These entities are currently heavily invested in support for WHO, and were strongly aligned with the introduction of newly restrictive outbreak responses that emphasized and sometimes mandated their products during the Covid-19 outbreak. Article 16. International collaboration and cooperation A somewhat pointless article. It suggests that countries cooperate with each other and the WHO to implement the other agreements in the Agreement. Article 17. Whole-of-government and whole-of-society approaches A list of essentially motherhood provisions related to planning for a pandemic. However, countries will legally be required to maintain a ‘national coordination multisectoral body’ for PPPR. This will essentially be an added burden on budgets, and inevitably divert further resources from other priorities. Perhaps just strengthening current infectious disease and nutritional programs would be more impactful. (Nowhere in this Agreement is nutrition discussed (essential for resilience to pathogens) and minimal wording is included on sanitation and clean water (other major reasons for reduction in infectious disease mortality over past centuries). However, the ‘community ownership’ wording is interesting (“empower and enable community ownership of, and contribution to, community readiness for and resilience [for PPPR]”), as this directly contradicts much of the rest of the Agreement, including the centralization of control under the Conference of Parties, requirements for countries to allocate resources to pandemic preparedness over other community priorities, and the idea of inspecting and assessing adherence to the centralized requirements of the Agreement. Either much of the rest of the Agreement is redundant, or this wording is purely for appearance and not to be followed (and therefore should be removed). Article 18. Communication and public awareness 1. Each Party shall promote timely access to credible and evidence-based information …with the aim of countering and addressing misinformation or disinformation… 2. The Parties shall, as appropriate, promote and/or conduct research and inform policies on factors that hinder or strengthen adherence to public health and social measures in a pandemic, as well as trust in science and public health institutions and agencies. The key word is as appropriate, given that many agencies, including the WHO, have overseen or aided policies during the Covid-19 response that have greatly increased poverty, child marriage, teenage pregnancy, and education loss. As the WHO has been shown to be significantly misrepresenting pandemic risk in the process of advocating for this Agreement and related instruments, its own communications would also fall outside the provision here related to evidence-based information, and fall within normal understandings of misinformation. It could not therefore be an arbiter of correctness of information here, so the Article is not implementable. Rewritten to recommend accurate evidence-based information being promoted, it would make good sense, but this is not an issue requiring a legally binding international agreement. Article 19. Implementation and support 3. The WHO Secretariat…organize the technical and financial assistance necessary to address such gaps and needs in implementing the commitments agreed upon under the Pandemic Agreement and the International Health Regulations (2005). As the WHO is dependent on donor support, its ability to address gaps in funding within Member States is clearly not something it can guarantee. The purpose of this article is unclear, repeating in paragraphs 1 and 2 the earlier intent for countries to generally support each other. Article 20. Sustainable financing 1. The Parties commit to working together…In this regard, each Party, within the means and resources at its disposal, shall: (a) prioritize and maintain or increase, as necessary, domestic funding for pandemic prevention, preparedness and response, without undermining other domestic public health priorities including for: (i) strengthening and sustaining capacities for the prevention, preparedness and response to health emergencies and pandemics, in particular the core capacities of the International Health Regulations (2005);… This is silly wording, as countries obviously have to prioritize within budgets, so that moving funds to one area means removing from another. The essence of public health policy is weighing and making such decisions; this reality seems to be ignored here through wishful thinking. (a) is clearly redundant, as the IHR (2005) already exists and countries have agreed to support it. 3. A Coordinating Financial Mechanism (the “Mechanism”) is hereby established to support the implementation of both the WHO Pandemic Agreement and the International Health Regulations (2005) This will be in parallel to the Pandemic Fund recently commenced by the World Bank – an issue not lost on INB delegates and so likely to change here in the final version. It will also be additive to the Global Fund to fight AIDS, tuberculosis, and malaria, and other health financing mechanisms, and so require another parallel international bureaucracy, presumably based in Geneva. It is intended to have its own capacity to “conduct relevant analyses on needs and gaps, in addition to tracking cooperation efforts,” so it will not be a small undertaking. Chapter III. Institutional and final provisions Article 21. Conference of the Parties 1. A Conference of the Parties is hereby established. 2. The Conference of the Parties shall keep under regular review, every three years, the implementation of the WHO Pandemic Agreement and take the decisions necessary to promote its effective implementation. This sets up the governing body to oversee this Agreement (another body requiring a secretariat and support). It is intended to meet within a year of the Agreement coming into force, and then set its own rules on meeting thereafter. It is likely that many provisions outlined in this draft of the Agreement will be deferred to the COP for further discussion. Articles 22 – 37 These articles cover the functioning of the Conference of Parties (COP) and various administrative issues. Of note, ‘block votes’ will be allowed from regional bodies (e.g. the EU). The WHO will provide the secretariat. Under Article 24 is noted: 3. Nothing in the WHO Pandemic Agreement shall be interpreted as providing the Secretariat of the World Health Organization, including the WHO Director-General, any authority to direct, order, alter or otherwise prescribe the domestic laws or policies of any Party, or to mandate or otherwise impose any requirements that Parties take specific actions, such as ban or accept travellers, impose vaccination mandates or therapeutic or diagnostic measures, or implement lockdowns. These provisions are explicitly stated in the proposed amendments to the IHR, to be considered alongside this agreement. Article 26 notes that the IHR is to be interpreted as compatible, thereby confirming that the IHR provisions including border closures and limits on freedom of movement, mandated vaccination, and other lockdown measures are not negated by this statement. As Article 26 states: “The Parties recognize that the WHO Pandemic Agreement and the International Health Regulations should be interpreted so as to be compatible.” Some would consider this subterfuge – The Director-General recently labeled as liars those who claimed the Agreement included these powers, whilst failing to acknowledge the accompanying IHR amendments. The WHO could do better in avoiding misleading messaging, especially when this involves denigration of the public. Article 32 (Withdrawal) requires that, once adopted, Parties cannot withdraw for a total of 3 years (giving notice after a minimum of 2 years). Financial obligations undertaken under the agreement continue beyond that time. Finally, the Agreement will come into force, assuming a two-thirds majority in the WHA is achieved (Article 19, WHO Constitution), 30 days after the fortieth country has ratified it. Further reading: WHO Pandemic Agreement Intergovernmental Negotiating Board website: https://inb.who.int/ International Health Regulations Working Group website: https://apps.who.int/gb/wgihr/index.html On background to the WHO texts: Amendments to WHO’s International Health Regulations: An Annotated Guide An Unofficial Q&A on International Health Regulations On urgency and burden of pandemics: https://essl.leeds.ac.uk/downloads/download/228/rational-policy-over-panic Disease X and Davos: This is Not the Way to Evaluate and Formulate Public Health Policy Before Preparing for Pandemics, We Need Better Evidence of Risk Revised Draft of the negotiating text of the WHO Pandemic Agreement: Published under a Creative Commons Attribution 4.0 International License For reprints, please set the canonical link back to the original Brownstone Institute Article and Author. Authors David Bell David Bell, Senior Scholar at Brownstone Institute, is a public health physician and biotech consultant in global health. He is a former medical officer and scientist at the World Health Organization (WHO), Programme Head for malaria and febrile diseases at the Foundation for Innovative New Diagnostics (FIND) in Geneva, Switzerland, and Director of Global Health Technologies at Intellectual Ventures Global Good Fund in Bellevue, WA, USA. View all posts Thi Thuy Van Dinh Dr. Thi Thuy Van Dinh (LLM, PhD) worked on international law in the United Nations Office on Drugs and Crime and the Office of the High Commissioner for Human Rights. Subsequently, she managed multilateral organization partnerships for Intellectual Ventures Global Good Fund and led environmental health technology development efforts for low-resource settings. View all posts Your financial backing of Brownstone Institute goes to support writers, lawyers, scientists, economists, and other people of courage who have been professionally purged and displaced during the upheaval of our times. You can help get the truth out through their ongoing work. https://brownstone.org/articles/the-who-pandemic-agreement-a-guide/ https://www.minds.com/donshafi911/blog/the-who-pandemic-agreement-a-guide-1621719398509187077
    BROWNSTONE.ORG
    The WHO Pandemic Agreement: A Guide ⋆ Brownstone Institute
    The commentary below concentrates on selected draft provisions of the latest publicly available version of the draft agreement that seem to be unclear or potentially problematic.
    Like
    1
    0 Comments 0 Shares 76244 Views
More Results